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SUMMARY 
 
Based on its prokaryotic nature, the apicoplast in Plasmodium falciparum is a unique 
target with great potential for generation of both chemotherapeutic and immunization 
intervention strategies against malaria. It is therefore essential to understand its 
biology. This study used a drug based approach to explore new aspects of apicoplast 
biology. 
In part 1 of this study the established antibiotic clindamycin was used to study 
biogenesis and function of the apicoplast during erythrocytic schizogony. The data in 
this study showed that during erythrocytic schizogony, clindamycin inhibits the egress 
machinery of the parasite by inhibiting the biogenesis and function of the apicoplast. 
Interestingly, in order to egress from erythrocyte, these parasites rely on an unusual 
early supplementation with isopentenyl pyrophosphate or zaprinast. The data in this 
study further showed that, the apicoplast in P. falciparum is required during egress by 
playing a role in the secretion of proteins required for egress. In this way, this study 
expands the current understanding of the biology of the apicoplast and the mode of  
action of this antibiotic during erythrocytic schizogony.  
In part 2 of this study, experimental antibiotics called acyldepsipeptides (ADEPS) 
were tested to determine whether they can target the biogenesis or function of the 
apicoplast in P. falciparum during erythrocytic schizogony and therefore whether they 
can be used as antimalarial drugs. The data in this study shows that ADEPS are able 
to inhibit growth of P. falciparum. On one hand, in parasites containing the apicoplast 
they appear to inhibit its biogenesis and or function. On the other hand, ADEPS also 
inhibit the growth of P. falciparum parasite lacking the apicoplast. Consequently, in P. 
falciparum, ADEPS appear to have apicoplast dependent targets and apicoplast 
independent targets. Never-the-less, ADEPS appear to be active against P. 
falciparum and therefore they can be invoked as antimalarial drugs. This study 
therefore contributes to the expansion of the arsenal to combat malaria. 
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ZUSAMMENFASSUNG 
 
Basierend auf seiner prokaryotischen Abstammung bietet der Apicoplast in 
Plasmodium falciparum (P. falciparum) ein einzigartiges Angriffsziel mit großem 
Potential für die Entwicklung von Chemotherapeutika und intervenierenden 
Immunisierungsstrategien gegen Malaria. Es ist daher wichtig, die Biologie des 
Apicoplasten zu verstehen. Diese Arbeit bedient sich eines Medikamenten-basierten 
Ansatzes, um neue Aspekte der Apicoplasten-Biologie zu erforschen. 
 
Im ersten Teil dieser Arbeit wurde das etablierte Antibiotikum Clindamycin 
verwendet, um die Biogenese und Funktion des Apicoplasten während der 
erythrozytären Schizogonie zu untersuchen.  Die ermittelten Daten zeigten, dass 
Clindamycin die Egress-Maschinerie der Parasiten während der erythrozytären 
Schizogonie hemmt, indem es die Biogenese und die Funktion des Apicoplasten 
unterdrückt. Interessanterweise ist für P. falciparum eine außergewöhnlich frühe 
Verfügbarkeit von Isopentenylpyrophosphat oder Zaprinast nötig um aus dem 
Erythrozyten herauszukommen. Des Weiteren zeigte sich in dieser Arbeit, dass der 
Apicoplast in P. falciparum für den Egress benötigt wird, da er eine Rolle in der 
Sekretion der für den Egress notwendigen Proteine spielt.  
In dieser Hinsicht erweitert diese Arbeit das Verständnis für die Biologie des 
Apicoplasten und die Wirkungsweise des Antibiotikums Clindamycin während der 
erytrhrozytären Schizogonie.  
 
Im zweiten Teil der Studie wurde untersucht, ob experimentelle Antibiotika, genannt 
Acyldepsipeptide (ADEPS), die Biogenese oder Funktion des Apicoplasten während 
der erytrozytären Schizoginie hemmen können und sich daher als Medikament 
gegen Malaria eignen würde. Es stellte sich heraus, dass ADEPS zwar das 
Wachstum von P. falciparum hemmen können, egal ob die Parasiten ein Apicoplast 
haben oder nicht. Dass heißt, in P. falciparum, gibt es zwei gruppe als Angriffsziele 
von ADEPS: das eine wo der Apicoplast abhängig ist und das andere wo der 
Apicoplast unabhängig ist. Aufgrund der bestehenden Wachstumshemmung können 
sie allerdingst trotzdem als Medikamente gegen Malaria eingesetzt werden.  
 
 
 7 
LIST OF ABBREVIATIONS 
 
ACP................Acyl Carrier Protein 
ACTs...............Artemisinin - based Combination Therapies  
ADEPS............Acyldepsipeptides 
BAS.................Blocking Aid Solution  
BSA.................Bovine Serum  Albumin 
Ca2+...............Calcium ions 
cDNA...............Complementary DNA    
CDPK5............Calcium Dependent Protein Kinase 5  
ClpP................Caseinolytic Protease  
CRT.................Chloroquine Resistance Transporter 
DHFR…………Dihydrofolate Reductase  
DHPS…………Dihydropterate Synthase  
DNA.................Deoxyribonucleic acid 
DMSO..............Dimethyl Sulfoxide 
E64..................trans - Epoxysuccinyl - L - leucylamido (4 - guanidino) butane  
Fe....................Iron 
FACS...............Fluorescence activated cell Sorter 
FITC.................Fluorescein Isothiocyanate 
FSC..................Forward Scatter  
g.......................gram 
I145TP.............Inositol 1,4,5 triphosphate  
IPP...................Isopentenyl Pyrophosphate 
IFA...................Immunofluorescence Assay  
Kb....................1,000 Nucleotide Bases 
l........................Liter 
n.......................Nano 
m......................Metre 
M......................Molar 
ml.....................Milliliter 
Mb....................Mega Base 
MFI...................Mean Fluorescence Intensity 
MSP.................Merozoite Surface Protein  
 8 
µ.......................micro 
PBS..................Phosphate Buffer Saline 
PCR..................Polymerase Chain Reaction 
Pfatl..................P. falciparum Arginine-tRNA ligase  
PfMDR1............P. falciparum Multi Drug Resistance 1 
PfPLPs.............P. falciparum perforin like proteins  
PfSUB1………..Plasmodium falciparum subtilisin like serine protease-1 
PI(3)P...............Phosphatidylinositol 3 Phosphate 
PI(4)P...............Phosphatidylinositol 4 Phosphate 
PI 4,5 BP..........Phosphatidylinositol 4,5 Bisphosphate 
PKG..................Protein kinase G  
RNA..................Ribonucleic Acid 
RT-PCR……….Real Time - Polymerase Chain Reaction  
S.......................Sulphur 
SERAs..............Serine Like Antigens  
SSC..................Side Scatter 
tRNA.................Transfer Ribonucleic Acid 
WHO.................World Health Organization  
 
 
 
 
 
 
 
 
 9 
LIST OF FIGURES 
 
Figure 1 Global malaria transmission. 
 
Figure 2 Malaria life cycle. 
 
Figure 3 Origin of the apicoplast. 
 
Figure 4 Experimental set up to determine clindamycin half maximum inhibitory 
concentrations and effects of clindamycin exposure after invasion. 
 
Figure 5 Experimental set up to synchronise clindamycin drug pressure and parasite 
cycle. 
 
Figure 6 Experimental set up to determine the effects of synchronised clindamycin 
drug pressure and parasite cycle on the apicoplast biogenesis in P. falciparum. 
 
Figure 7 Experimental set up to rescue clindamycin treated parasites with IPP. 
 
Figure 8 Experimental set up to determine rescue of clindamycin treated parasites 
with zaprinast. 
 
Figure 9 Experimental set up to mechanically induce egress of clindamycin arrested 
schizonts. 
 
Figure 10 Experimental set up to determine the effects of clindamycin-induced 
inhibition of the apicoplast biogenesis on PfSUB1 expression. 
 
Figure 11 Experimental set up to determine effects of clindamycin induced inhibition 
of the apicoplast function on PfSUB1 secretion in P. falciparum. 
 
Figure 12 Experimental set up to determine effects of clindamycin induced inhibition 
of the apicoplast function on calcium signalling. 
 
Figure 13 Experimental set up to determine effects of clindamycin induced inhibition 
of the apicoplast function on phosphoinositide metabolism. 
 
Figure 14 Experimental set up to determine in vitro activity of ADEPS against P. 
falciparum. 
 
Figure 15 Experimental set up to ADEPS effects of ADEP4 on apicoplast biogenesis 
in P. falciparum. 
 
Figure 16 Experimental set up to determine effects of ADEP4 on apicoplast function. 
 
Figure 17 Experimental set up to determine whether the apicoplast is the target for 
ADEPS. 
 
Figure 18 Half maximum inhibitory concentration values (IC50) of clindamycin. 
 
 10 
Figure 19 Growth inhibition of P. falciparum treated with clindamycin 6 hours post 
invasion. 
 
Figure 20 Growth inhibition of P. falciparum on treatment with clindamycin before 
invasion. 
 
Figure 21 Thin smears of P. falciparum in vitro cultures during the second cycle post 
invasion. 
 
Figure 22 Effects of clindamycin on the apicoplast biogenesis in P. falciparum during 
the first half of the first cycle. 
 
Figure 23 Effects of clindamycin on the apicoplast biogenesis in P. falciparum during 
the second half of the first cycle. 
 
Figure 24 Effects of clindamycin on the apicoplast biogenesis in P. falciparum during 
the first half of the second cycle. 
 
Figure 25 Effects of clindamycin on the apicoplast biogenesis in P. falciparum during 
the second half of the second cycle. 
 
Figure 26 IPP rescue of clindamycin treated parasites at different time points post 
invasion. 
 
Figure 27 Effect of zaprinast on Plasmodium falciparum. 
 
Figure 28 Zaprinast rescue of clindamycin arrested schizonts at different time points 
post invasion. 
 
Figure 29 Invasion assay at 12 hours post invasion. 
 
Figure 30 Assay of PfSUB1 expression. 
 
Figures 31 Immunofluorescence assay of PfSUB1 at the end of the second cycle in 
untreated parasites 
 
Figures 32 Immunofluorescence assay of PfSUB1 at the end of the second cycle in 
clindamycin treated parasites. 
 
Figures 33 Immunofluorescence assay of PfSUB1 at the end of the second cycle in 
clindamycin treated parasites and rescued with IPP. 
 
Figures 34 Immunofluorescence assay of PfSUB1 at the end of the second cycle in 
clindamycin treated parasites and rescued with zaprinast. 
 
Figures 35 Levels of free intracellular calcium ion measured at the end of the second 
cycle. 
 
Figures 36 Levels of phosphatidylinositol 3 phosphate (PI3P) measured at the end of 
the second cycle. 
 
 11 
Figures 37 Levels of phosphatidylinositol 4 phosphate (PI4P) measured at the end of 
the second cycle. 
 
Figure 38 Growth inhibition assay of ADEP1 on P. falciparum. 
 
Figure 39 Growth inhibition assay of ADEP4 on P. falciparum.  
 
Figure 40 Response of P. falciparum to treatment with ADEP 4 at 10 µg/ml. 
 
Figure 41 Effects of ADEPS on the biogenesis of the apicoplast during the first (A) 
and second cycle (B). 
 
Figure 42 Growth inhibition assay of ADEP4 on P. falciparum under IPP provision. 
 
Figure 43 Response of P. falciparum to treatment with ADEP4 at 10 µg/ml under 
exogenous provision with IPP. 
 
Figure 44 Chemical knock-out of the apicoplast. 
 
Figure 45 Chemical rescue of clindamycin treated parasites with IPP. 
 
Figure 46 Growth inhibition assay of ADEP4 on P. falciparum without the apicoplast 
under IPP provision. 
 
Figure 47 Summary 
 
Supplementary Figure 1 Agarose gel electrophoresis to confirm lack of DNA 
contamination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 12 
LIST OF TABLES 
Table 1........................Primers  
Table 2........................PCR conditions used to confirm lack of DNA contamination  
Table 3........................RT PCR conditions 
  
 13 
TABLE OF CONTENTS 
ACKNOWLEDGEMENT	........................................................................................................	4 
SUMMARY	.........................................................................................................................	5 
ZUSAMMENFASSUNG	........................................................................................................	6 
LIST	OF	ABBREVIATIONS	.....................................................................................................	7 
LIST	OF	FIGURES	.................................................................................................................	9 
LIST	OF	TABLES	.................................................................................................................	12 
INTRODUCTION	................................................................................................................	15 
Malaria .................................................................................................................................................... 15 
Plasmodium falciparum life Cycle ......................................................................................................... 15 
Adaptation of P. falciparum during the blood stage .............................................................................. 17 
Malaria intervention strategies ............................................................................................................... 19 
Antimalarial drugs .................................................................................................................................. 19 
Antimalarial drug resistance ................................................................................................................... 20 
Apicoplast ............................................................................................................................................... 21 
The origin of the apicoplast ............................................................................................................... 21 
Functions of the apicoplast ................................................................................................................ 23 
Biogenesis of the apicoplast ............................................................................................................... 23 
The apicoplast as a target for antibiotics .......................................................................................... 24 
Clindamycin ........................................................................................................................................... 25 
Acyldepsipeptides ................................................................................................................................... 26 
Aim of the study ..................................................................................................................................... 26 
MATERIALS	AND	METHODS	..............................................................................................	27 
Materials ................................................................................................................................................. 27 
A. Equipment ...................................................................................................................................... 27 
B. Material ......................................................................................................................................... 28 
C. Reagents ........................................................................................................................................ 28 
Methods .................................................................................................................................................. 30 
Cell Culture ........................................................................................................................................ 30 
In vitro drug sensitivity assay and classical delayed death assay ..................................................... 30 
In vitro Clindamycin Exposure Before Invasion ................................................................................ 32 
Determination of the effect of synchronising clindamycin drug pressure and parasite cycle on the 
Apicoplast biogenesis ......................................................................................................................... 33 
Rescue Of Clindamycin Arrested Schizonts With Isopentenyl Pyrophosphate .................................. 35 
Induction of Egress with Zaprinast .................................................................................................... 36 
Mechanical rupture of clindamycin-arrested schizonts ..................................................................... 36 
Determination Of The Effects Of Clindamycin-Induced Inhibition Of The Apicoplast Biogenesis On 
Pfsub1 Expression .............................................................................................................................. 37 
Determination of The Effects Of Clindamycin-Induced Inhibition Of The Apicoplast Biogenesis On 
Secretion Of Pfsub1 ........................................................................................................................... 39 
Determination of The Effects Of Clindamycin-Induced Inhibition Of The Apicoplast Biogenesis On 
Ca2+ Signalling ................................................................................................................................... 41 
Determination of The Effect Of Clindamycin-Induced Inhibition Of The Apicoplast Biogenesis On 
Phosphoinositides Metabolism .......................................................................................................... 42 
Determination of ADEPS In vitro activity against Plasmodium falciparum ..................................... 43 
Determination of the effects of ADEP4 on apicoplast biogenesis ..................................................... 45 
 14 
Determination of the effects of ADEP4 on apicoplast function ......................................................... 46 
Chemical Knock - Out of the apicoplast ............................................................................................ 47 
Data Analysis ..................................................................................................................................... 48 
RESULTS	...........................................................................................................................	49 
Part 1 ....................................................................................................................................................... 49 
Clindamycin causes an egress defect of P. falciparum ...................................................................... 49 
Inhibition of egress correlates with inhibition of the apicoplast biogenesis. .................................... 52 
Chemical complementation of the apicoplast function reverses egress defects ................................ 57 
Zaprinast induces egress of Clindamycin-arrested schizonts ............................................................ 58 
Mechanically released merozoites from clindamycin-arrested schizonts are non-invasive .............. 60 
Clindamycin-induced inhibition of the apicoplast does not inhibits expression of PfSUB1 .............. 61 
Clindamycin-induced inhibition of the apicoplast inhibits secretion of PfSUB1 .............................. 63 
Clindamycin-induced inhibition of the apicoplast does not inhibit calcium signaling and 
phosphoinositide metabolism ............................................................................................................. 68 
Clindamycin-induced inhibition of the apicoplast does not inhibit phosphoinositide metabolism ... 69 
Part 2 ....................................................................................................................................................... 72 
ADEP 4 slows down the cell cycle of Plasmodium falciparum ......................................................... 72 
ADEP4 induces filamentation of the apicoplast ................................................................................ 74 
Chemical complementation with IPP does not rescue ADEP4 treated parasites .............................. 76 
Chemical knockout of the apicoplast does not rescue ADEP4 treated parasites .............................. 77 
DISCUSSION	.....................................................................................................................	80 
Part 1 ....................................................................................................................................................... 80 
Clindamycin induced inhibition of apicoplast biogenesis and P. falciparum growth ............................ 80 
Egress Mechanism ............................................................................................................................. 80 
Biogenesis and function of the apicoplast .......................................................................................... 81 
Maintenance of the apicoplast ........................................................................................................... 82 
Part 2 ....................................................................................................................................................... 86 
Acyldepsipeptides induced inhibition of apicoplast biogenesis and P. falciparum growth ................... 86 
CONCLUSIONS	AND	RECOMMENDATIONS	.......................................................................	89 
REFERENCES	.....................................................................................................................	90 
APPENDIX	......................................................................................................................	104 
Supplementary Data ............................................................................................................................. 104 
MANUSCRIPTS	...............................................................................................................	105 
Isopentenyl pyrophosphate links apicoplast function to egress; two different biological processes in 
Plasmodium falciparum ........................................................................................................................ 105 
Acyldepsipeptides slows down the cycle of Plasmodium falciparum during erythrocytic schizogony
 .............................................................................................................................................................. 135 
 
 
 
 
 
 
 
 
 15 
INTRODUCTION 
Malaria 
 
The phylum Apicomplexa comprises of unicellular obligate endoparasites. These 
organisms have a characteristic cellular organelle called the apical complex. This 
organelle is employed for the invasion of the host cell. Members of this group include 
Toxoplasma, Isospora, Cryptosporidium, Cyclospora, Babesia, Eimeria and 
Plasmodium. These parasites cause toxoplasmosis, isosporiasis, cryptosporidiosis, 
cyclosporiasis, babesiosis, coccidiosis and malaria respectively.  
Malaria continues to be a global health challenge (Figure 1). Basing on the world 
health organisation (WHO) report, during the year 2015, 214 million people were 
infected with malaria and 438,000 died from malaria (WHO 2015 A). 
 
 
Figure 1 Global malaria transmission (Source: WHO 2014 A). Malaria s predominantly concentrated along the tropical 
countries. Most of the this burden lay in Africa (WHO 2015). 
Plasmodium falciparum life Cycle 
 
Malaria is a disease that results from infection with Plasmodium. Five species of 
Plasmodium can infect human beings, namely:  Plasmodium falciparum, Plasmodium 
vivax, Plasmodium malariae, Plasmodium ovale and Plasmodium knowlesi 
(Stephens 1914; Chin et al., 1968; Escalante et al., 1995; Escalante and Ayala 
1995). Among these species, P. falciparum is the most dangerous (WHO 2015).  
P. falciparum is an intracellular parasite and its life cycle (Figure 2) occurs in the 
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female Anopheles mosquito and human being. The infection starts from a bite by an 
infected mosquito. The respective parasite stage known as sporozoite enters the 
bloodstream. It then proceeds to the liver and invades hepatocyte. Here it initiates a 
phase of its life cycle called liver stage which is characterized by parasite 
transformation and asexual multiplication. This produces thousands of daughter cells 
known as merozoites contained in a structure called merosome. Merozoites get 
released from the infected liver cell into the blood stream in a process called egress. 
Here they bind to and invade erythrocytes initiating another phase of the parasite´s 
life cycle called erythrocytic schizogony i.e. the blood stage. 
Within the erythrocytes, the parasite undergoes transformation also into different 
forms called rings, trophozoites and eventually into schizonts. During the schizont 
stage, the parasite undergoes asexual multiplication resulting in about 10-32 
merozoites. These merozoites are in-turn released from the infected erythrocytes 
also through the egress process. They then invade uninfected erythrocytes to further 
growth of the parasite. It is the continuous rupturing of the erythrocytes which 
interferes with their physiological function leading to the clinical symptoms associated 
with malaria disease (Lodish et al., 2003). Some merozoites transform into 
gametocytes which are then taken up by the mosquito during a blood meal. In the 
mosquito, gametocytes egress from erythrocytes, reproduce sexually eventually 
generating thousands of sporozoites contained within an oocyst in the midgut of the 
mosquito. These sporozoites in turn also egress in order to continue the parasite’s 
life cycle.  
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Figure 2 Malaria life cycle (Source: Cowman et al., 2012). Once an infected mosquito bites a person sporozoites enter the 
bloodstream and migrate to the liver. Here the parasite undergoes transformation and multiplication giving rise to merozoites 
that infect erythrocytes. Here the parasite undergoes again transformation and multiplication producing more merozoites. The 
parasite transforms also into sexual forms known as gametocytes which are taken up by a mosquito during a blood meal. There 
they undergo the sexual phase of the parasite life cycle. This in turn produces sporozoites which continue the parasite’s life 
cycle. 
Adaptation of P. falciparum during the blood stage 
 
During the blood stage the parasite has evolved some interesting mechanisms that 
promote its survival within erythrocytes, which have been exploited for experimental 
strategies to understand the biology of the parasite and generation of intervention 
strategies. Some of these mechanisms lay the basis of my key experimental 
procedures. 
The merozoite has a size of about 1.2 µm (Boyle et al., 2010 B). It has a surface 
coat, cytoskeleton and organelles. The organelles are; nucleus, mitochondrion, 
ribosomes, endoplasmic reticulum, Golgi apparatus and the apical complex. The 
apical complex contains a number of secretory organelles which include rhoptries, 
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micronemes, exonemes and dense granules (Cowman et al., 2012). 
During the invasion process, the parasite has to first make contact with the 
erythrocyte before penetrating it. This requires a parasite ligand called merozoite 
surface protein (MSP) to bind to receptors on the erythrocytes. This interaction can 
be inhibited by heparin thereby preventing invasion (Boyle et al., 2010 A). 
After penetrating the erythrocytes, it then uses the host cell membrane to form a 
parasitophorous vacuole, which houses the parasite (Lingelbach and Joiner 1998). 
As the parasite starts to mature and grow, it exports proteins to the host cell and 
remodels the host cell plasma membrane. These play important roles in nutrient 
acquisition and protection against the immune system (Lodish et al., 2003; Goldberg 
and Cowman 2010). Because these membrane remodeling are extensive in older 
parasite stages and absent in rings, exposure of the parasites to 5% D-Sorbitol can 
be used to get rid of trophozoites and schizonts (Lambros and Vanderberg 1979). 
The parasite salvages proteins from the erythrocytes by actively importing 
haemoglobin and enzymatically digesting it in the food vacuole. Heme as a toxic by-
product of this process is converted to non toxic hemozoin (Olliaro and Goldberg 
1995). Iron as a building block of heme can be exploited to magnetise the 
trophozoites and schizonts, thereby separating them from rings and uninfected 
erythrocytes which lack the food vacuole (Paul et al., 1981). 
The parasite has a genome of 23 Mb distributed over 14 chromosomes (Gardner et 
al., 2002). During the blood stage it reproduces asexually by schizogony. This is a 
unique type of mitosis in which the parasite undergoes several rounds of 
unsynchronised mitotic division within the mother cell. This is later followed by a 
uniform final round of mitotic division and assembly of the daughter cells (Francia 
and Striepen 2014).  
This asynchronous division yields about 10 – 32 merozoites. In order to egress the 
host cell, the parasite degrades the parasitophorous vacuole membrane and the 
erythrocytes membrane. Since this process requires cysteine proteases, it can 
therefore be inhibited by the compound trans - Epoxysuccinyl - L - leucylamido (4 - 
guanidino) butane (E64, from Sigma aldrich). This inhibition trap the merozoites 
within the host cell (Salmon et al., 2001). These merozoites can then be released 
and purified by mechanically rupturing the schizonts by filteration through a 1.2 µm 
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membrane syringe filter (Boyle et al., 2010 B). 
Malaria intervention strategies 
 
Malaria can be prevented or cured. Since the year 2000, owing to intervention 
strategies there has been a reduction of 18% and 48% in the morbidity and mortality 
resulting from malaria respectively (WHO 2015). Prevention of transmission is done 
through vector control using long lasting insecticide treated bed nets and in door 
residual spraying  (WHO 2015). Treatment is by the use of antimalarial drugs and it 
would also ideally involve vaccination, but upto now no malaria vaccine has been 
licensed (WHO 2015).  
Antimalarial drugs 
 
There are various antimalarial drugs with different modes of action. These can be 
broadly classified into the following groups: aminoquinolines, arylaminoalcohols, 
artemisinines, antifolates, inhibitors of the respiratory chain and antibiotics (Schlitzer 
2008). Aminoquiolines include 4-aminoquinolines e.g. chloroquine and 8-
aminoquinolones e.g. primaquine. During the blood stage, the parasite digests 
hemoglobin in its food vacuole. This process produces heme, which is toxic to the 
parasite. Heme is subsequently converted to hemozoin, in order to neutralize it 
(Olliaro and Goldberg 1995). 4-aminoquinolines act by inhibiting this process. 
Arylaminoalcohols inhibit digestion of hemoglobin. Drugs in this group are quinine, 
mefloquine, halofantrine and lumefantrine. Artemisinins include artemether and 
artesunate. These drugs act by first being transformed into dihydroartemsisinin, 
which is the active molecule (Luo and Shen 1987). This has endoperoxide bonds, 
which upon reaction with iron produce radicals that are toxic to the parasites 
(Meshnick et al., 1993). Antifolates act as inhibitors of dihydrofolate reductase 
(DHFR) or dihydropterate synthase (DHPS) in the folate biosynthesis pathway. They 
include: sulfadoxine, pyrimethamine, dapsone and chlorpoguanil. Inhibitors of the 
respiratory chain include atovaqoune (Schlitzer 2008). It acts by binding to 
cytochrome bc1 complex, thereby inhibting the generation of mitochondrial 
membrane potential (Fry and Pudney 1992; Srivastava et al., 1997; Kessl et al., 
2003; Schlitzer 2008).  
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Antimalarial drug resistance 
 
Despite the availability of all of these antimalarial drugs, the malaria parasite has 
however developed various mechanisms which reduce their activities and therefore 
their application. Resistance to 4-aminoquinolines is known to result from mutations 
in the gene that encodes a protein called chloroquine resistance transporter (CRT). 
This reduces the activity of these drugs by removing them from the food vacuole 
(Fidock et al., 2000). Amplification of the gene encoding a transport protein known as 
P. falciparum multidrug resistance 1 (PfMDR1), has been associated with reduced 
activity of Arylaminoalcohols (Peel et al., 1994; Woodrow and Krishna 2006). 
Resistance to artemisinins is associated with parasite dormancy (Teuscher et al., 
2010), a phenomenon attributed to an overactivated phosinositidyinositol - 3 - kinase 
(PI3K) and consequently phosphoinositydylinositol - 3 - phosphate metabolism 
(PI3P) (Mbegue et al., 2015). Resistance to antifolates is due to single point 
mutations in the genes that code for DHFR or DHPS (Triglia et al., 1997; Peterson et 
al., 1988). Resistance to atovaqoune occurs due to single point mutations in the gene 
that codes for cytochrome b (Walker et al., 1998). 
How and why the parasite develops resistance is due to a number of different factors, 
namely: mutations in parasite, cross drug resistance, multiple drug resistance, 
pharmacokinetics, drug half-life, host immunity, transmission, vector and environment 
(Sinha et al., 2014). Initially, drug resistance starts due to spontaneous single or 
multiple point mutations that naturally occur. These mutations convert the genetic 
make up of wild type parasites. This in turn transforms them to mutants which do not 
respond to drug treatment in different ways: the mutations may change the affinity of 
the drug to its target. Or they may inhibit accumulation of the drug inside the parasite. 
These mutants in turn multiply giving rise to more drug resistant parasites. Emerged 
drug resistance may then become complicated by several factors. Parasites may 
become resistant to drugs belonging to the same family or having a similar mode of 
action. This is called cross drug resistance. Parasite may also become resistant to 
more than one antimalarial drug. This is known as multiple drug resistance. Owing to 
poor understanding of pharmocokinetics dynamics involving drug concentration vs 
parasite sensitivity or resistance, insufficient dosage may be used in the treatment of 
resistant parasites, thereby selecting them instead of clearing them, therefore, 
promoting their expansion. Some drugs have longer half lives. They therefore remain 
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in the circulation for a long time. This act as a form of drug pressure, which although 
may eliminate sensitive parasites, the concentration may not be sufficient to eliminate 
resistant parasites. Therefore, promoting their proliferation. The extent to which 
resistant parasites proliferate is also governed by the host immunity. This is because 
if the immune system is able to clear parasites resistant to antimalarial drugs, then 
they will not proliferate. On the contrary, if it is not able to clear them then they will 
proliferate. Immunity governs also the rate at which malaria symptoms develop. 
People from high malaria transmission areas e.g. Africa, develop partial immunity to 
malaria with time. They therefore, do not easily develop malaria symptoms as 
compared to people from low transmission areas like the southeast of Asia. Due to 
this reason antimalarial drugs are highly likely to be used alot in the latter. This can 
be a source of drug pressure in this region increasing the chances of selecting 
resistant parasites which can spread to the former region (Sinha et al., 2014). 
Development of parasite resistance to antimalarial drugs limits the fight against 
malaria. The WHO therefore recommends the use of artemisinin - based combination 
therapies (ACTs) to combat malaria (WHO 2015). As the name suggests, in this 
strategy artemisinin drugs are combined with other antimalarial drugs. However, 
there are reports of resistance to artemisinins (Dondorp et al., 2009; Ashley et al., 
2014; WHO 2014 B). As a back up measure, antibiotics in combination with other 
antimalarial drugs are recommended by the WHO as antimalarial drugs (WHO 2015 
B) and they are currently being used against artemisinin or ACTs resistant parasites 
(Dondorp et al., 2009). 
Apicoplast 
The origin of the apicoplast 
 
Except the species Cryptosporidium (Xu et al., 2004), parasites belonging to the 
phylum Apicomplexa have a plastid called the apicoplast (Lang-Unnasch et al., 
1998). It was discovered a few decades ago (Kilejian A 1975; Borst et al., 1984; 
Wilson et al., 1996), to have originated through the process of secondary 
endosymbiosis (Lim and McFadden 2010). This process involved; a unikont which 
engulfed a cyanobacterium giving rise to a red algae. The latter was then engulfed by 
a bikont, followed by genetic rearrangements with the transfer of most of its DNA  
into the bikont (Lim and McFadden 2010) (Figure 3). 
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As a consequences of these endosymbiotic processes; the apicoplast genome was 
reduced to 35 Kb containing 64 genes (Wilson et al., 1996); it is surrounded by four 
membranes (Köhler S et al., 1997; McFadden and Roos 1999; McFadden 2010) and 
it relies on about 540 proteins that it has to import from the host cell (Waller et al., 
1998). This imported proteins have to cross the four membranes surrounding it and 
this occurs by post-translationally targeting of these proteins to the apicoplast via a 
bipartite leader signal, that consists of a signal sequence and a transit signal 
(DeRocher et al., 2001; Waller et al., 2000). These signals function to aid the co-
translation importation of proteins into the endo-membrane system and sorting into 
the apicoplast respectively (Waller and McFadden 2005). Within the apicoplast, 
these proteins function in the expression of its genome (Waller et al., 1998) or in the 
metabolic pathways that it hosts (Ralph et al., 2004).  
 
Figure 3 Origin of the apicoplast (Source: Howe and Purton 2007). The apicoplast resulted from two endosymbiotic events 
between two eukaryotic cells and one prokaryotic cell followed by genetic rearrangements. 
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Functions of the apicoplast 
 
The apicoplast hosts a number of metabolic pathways; the type II fatty acid 
synthesis, non-mevalonate isoprenoid synthesis, heme biosynthesis, Fe-S cluster 
biosynthesis, lipoate synthesis, tRNA modifications and ferredoxin redox system 
(Ralph et al., 2004). In return, products of these pathways are essential for the 
parasite. The apicoplast functions during the mosquito stage to produce heme 
(Nagara et al., 2013; Ke et al., 2014), during liver stage to produce fatty acids (Yu et 
al., 2008; Vaughan et al., 2009) and during the blood stage to produce isoprenoid 
precursors known as isopentenyl pyrophosphate (IPP) (Jomaa et al., 1999; Ye and 
DeRisi 2011; Wiley et al., 2015). 
The products of the isoprenoid biosynthetic pathway (among other roles) are 
essential for post-translational modifications of proteins especially the anchorage to 
membranes (Alberts et al., 2008; Howe et al., 2013). Therefore, the apicoplast as an 
essential organelle is a validated drug target (Jomaa et al., 1999; Waller and 
McFadden 2005; Yu et al., 2008; Goodman et al., 2007; Ye and DeRisi 2011). 
Biogenesis of the apicoplast 
 
There is only one copy of the apicoplast in the Plasmodium parasite (Waller and 
McFadden 2005) and it is a very essential organelle (Jomaa et al., 1999; Ye and 
DeRisi 2011; Yu et al., 2008; Vaughan et al., 2009; Niagara et al., 2013; Ke et al., 
2014; Wiley et al., 2015). Because it cannot be synthesised denovo, it has to be 
inheritated from the mother cell. For this to happen, it undergoes biogenesis in the 
course of the parasite’s life cycle in hepatocytes, erythrocytes and in the midgut wall 
of the mosquito. It is then later segregated to the daughter cells towards the end of 
the cycle (Waller and McFadden 2005; Stanway et al., 2009).  
How this occurs, is that, its biogenesis is coupled to the parasite transformation and 
cell division. During the early ring stage the apicoplast appears as a rod shaped and 
slightly curved structure. It then develops into a spherical structure. As the ring stage 
transforms into a trophozoite stage, it slowly increases in size but still remains as a 
spherical structure. It then grows, increases in length and branches forming a multi-
branched structure in the transition from late trophozoite into early shizont stage. 
During this transition, the nucleus of the parasite undergoes mitosis to form multiple 
nuclei. Division of the apicoplast is delayed until this process is completed. 
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Therefore, it remains as a multibranched structure until late schizont stage. It is then 
segregated followed by cytokinesis of the parasite to form merozoites. These then 
egress, each carrying only one copy of the apicoplast (Waller and McFadden 2005).  
The apicoplast as a target for antibiotics 
 
The apicoplast has a 35 Kb genome (Wilson et al., 1996) and a number of metabolic 
pathways (Ralph et al., 2004). Due to its prokaryotic nature (Wilson et al., 1996), it is 
amenable to inhibition by antibiotics (Surolia et al., 2004; Burkhardt et al., 2007; Dahl 
and Rosenthal 2007; Goodman et al., 2007; Friesen et al., 2010). These antibiotics 
target the apicoplast differently (Waller and McFadden 2005; Goodman et al., 2007) 
and they can be classified into two groups: Those that inhibit house keeping 
functions and those that inhibit metabolic pathways.  
Ciprofloxacin blocks DNA replication by inhibitng DNA gyrase (Divo et al., 1988). 
Rifampicin blocks transcription by inhibiting prokaryotic RNA polymerase (Calvori et 
al., 1965). Several other antibiotics inhibit protein translation e.g. doxycycline, 
tetracyclines, chloramphenicol, azithromycin, thiostrepton and clindamycin (Waller 
and McFadden 2005; Goodman et al., 2007). Doxycycline and tetracyclines act by 
binding to the prokaryotic 16S ribosomal RNA (Budimulja et al., 1997), while 
chloramphenicol, thiostrepton, azithromycin, and clindamycin act by binding to the 
prokaryotic 23S ribosomal RNA (Drainas et al., 1987; Pfefferkorn and Borotz 1994; 
Beckers et al., 1995; Tenson et al., 2003; Dharia et al., 2010).  
Inhibitors of non-house keeping functions include: fosmidomycin which by targeting 
1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibits the non mevalonate 
isoprenoid biosynthesis pathway (Jomaa et al., 1999); Triclosan and thiolactomycin 
which inhibit the type II fatty acid biosynthesis pathway by targeting FabI and FabF/H 
enzymes of this pathway respectively (Surolia and Surolia 2001; Waller et al., 2003). 
By acting on different targets these antibiotics inhibit the parasite growth differently 
during the blood stage: ciprofloxacin, rifampicin and thiostrepton inhibit parasite 
growth within one cycle (Goodman et al., 2007). Tetracyclines and clindamycin inhibit 
parasite growth after two cycles, a phenomena termed delayed death (Surolia et al., 
2004; Burkhardt et al., 2007; Dahl and Rosenthal 2007; Goodman et al., 2007).  
The antibiotics clindamycin and azithromycin have been used to demonstrate that it 
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is possible to generate a whole organism based vaccine against malaria. Whereby, 
infecting mice with sporozoites and at the same time treating them with these 
antibiotics, the apicoplast biogenesis becomes inhibited. However, these parasites 
mature forming metabolically active merosomes, which provide a source of 
immunization against rodent malaria (Friesen et al. 2010). 
Clindamycin 
 
Clindamycin is an antibacterial drug belonging to lincosamide group of antibiotics. It 
is synthesised from the antibiotic lincomycin (Birkenmeyer and Kagan 1970; Spizek 
and Rezanka 2004). It acts by binding to the 23S ribosomal RNA in the large subunit 
ribosome in prokaryotes (Dharia et al., 2010). This prevents ribosomal translocation 
during protein synthesis. Consequently this leads to the inhibition of protein 
translation (Pfefferkorn and Borotz 1994; Camps et al., 2002; Tenson et al., 2003). 
 
This effect of inhibiting protein synthesis has been shown to lead to inhibition of the 
apicoplast biogenesis (Dahl and Rosenthal 2007; Goodman et al., 2007). 
Consequently, the daughter cells formed within the mother cell do not get a copy of 
the apicoplast. This results in the inhibition of the parasite (Dahl and Rosenthal 2007; 
Goodman et al., 2007). However, this clindamycin-induced inhibition of the apicoplast 
biogenesis and parasite growth has been shown to occur differently during the 
parasite cycle: 
 
• During the liver stage, exposure of clindamycin to sporozoites before invasion, 
results in the parasites developing into full maturity with no difference to untreated 
parasites. However, the biogenesis of the apicoplast in these parasites is inhibited 
(Friesen et al., 2010).  
• In contrast, during the blood stage, exposure of clindamycin to the parasite post 
invasion results in normal parasite growth and apicoplast development. These 
parasites are then able to egress, invade unifected erythrocytes but inhibition of 
the apicoplast biogenesis occurs. Consequently this leads to arrest of parasite 
growth (Surolia et al., 2004; Burkhardt et al., 2007; Dahl and Rosenthal 2007; 
Goodman et al., 2007). 
Therefore, does the difference in the exposure of clindamycin before invasion during 
the liver stage and exposure post invasion during the blood stage, have an influence 
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on its effects on the observed differences; in the timing of the inhibition of the 
apicoplast biogenesis and parasite growth? In order to clarify this discrepancy, an 
ideal approach would be to set up a clear cut experiment during the blood stage by 
starting with the exposure of clindamycin to  merozoites before invasion. 
Acyldepsipeptides  
 
Acyldepsipeptides (ADEPS) are a new type of antibacterial drugs produced from a 
parent molecule called A54556 complex (Michel and Kastner 1985; Brötz - 
Oesterhelt et al., 2005). In bacteria, ADEPS act via a unique mode of action (Brötz - 
Oesterhelt et al., 2005). They bind to ClpP protease, activating it uncontrollably 
(Brötz - Oesterhelt et al., 2005; Gersch et al., 2014). The unregulated ClpP then 
preferentially targets bacterial cell division machinery (Brötz - Oesterhelt et al., 2005; 
Sass et al., 2011). This results in the inhibition of bacterial cell division. The parasite 
ends up as filamented or swollen cells (Sass et al., 2011; Brötz - Oesterhelt et al., 
2005). Since the apicoplast is bacterial in nature (Wilson et al., 1996) and has a ClpP 
protease too (Bakkouri et al., 2010), therefore, can ADEPS target the apicoplast and 
be used as antimalarial drugs? 
Aim of the study  
 
The main aim of this study was to expand the understanding of the biology of the 
apicoplast as a unique target for development of antimalarial intervention strategies.  
 
1. The first part of this study used the classical antibiotic called clindamycin to 
study the effects of synchronised antibiotic drug pressure and parasite cycle, 
to the biogenesis of the apicoplast and growth of P. falciparum during blood 
stage, and to follow-up the emerging phenotype by doing detailed studies.  
2. The second part of this study used new types of antibiotics called 
Acyldepsipeptides (ADEPS), to determine whether they can inhibit the 
biogenesis and funtion of the apicoplast in P. falciparum, and therefore 
whether they can be used as antimalarial drugs. 
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MATERIALS AND METHODS     
Materials 
A. Equipment 
1. Incubator (37°C)  
2. Technical gas (92% N2, 5% CO2, 3% O2) 
3. Laminar flow hood  
4. Centrifuge (Heraus Megafuge 1.0 R) 
5. Light Microscope (Nikon Eclipse E200)  
6. Electronic pipette dispenser (Integra Pippetboy) 
7. Balance (Ohaus Adventurer Pro) 
8. Magnetic stirrer (Heidoplh MR3001) 
9. Vacuum pump  
10. Water bath (E5 Medingen) 
11. Liquid nitrogen tank (ARPEGER 170) 
12. Freezer (-80°C) (Heraus Hera freezer) 
13. Freezer (-20°C) (Premium Liebherr) 
14. Refrigerator (4°C) (Premium Liebherr) 
15. pH metre (Schot Instruments Lab 850) 
16. VarioMACSTM separation magnet system and columns (Miltenyi Biotec) 
17. Facs machine (BD) 
18. PCR machine (Eppendorf master cycler epgradient S) 
19. qPCR machine (CR Corbert Research) 
20. Nano drop (Nanodrop®) 
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21. Microwave (LG Intellowave) 
22. Gel doc (Haiser R1, RS Dark reader Illuminator) 
23. Fluorescence microscope (Zeiss Observer.Z1) 
B. Material 
1. Cell culture flasks with filter bottle top (Greiner bio-one T25/T75)  
2. Sterile tubes (Greiner bio-one, 15 ml/50 ml) 
3. Sterile serological pipettes (Greiner bio-one, 1 ml, 2 ml, 5 ml, 10 ml, 25 ml) 
4. Glass Pasteur capillary pipettes (WU Mainz, long size, 230mm) 
5. Glass slides (Thermo Scientific, ground edges, frosted ends) 
6. Sterile filter units (Millipore, Steritop, 0.22 µm for 500 ml bottles) 
7. Sterile syringe filter (Roth, 0.22 µM) 
8. Sterile syringe (BD, 5, 10 and 20 ml) 
9. Cryo - vials (Greiner bio-one) 
10. 96 well plates (Greiner bio-one) 
11. Multichannel pipette (Eppendorf) 
12. Pipettes (Eppendorf Research) 
13. Aluminum paper foil (Universal) 
14. PAP Pen (Sigma Aldrich) 
15. Poly - L - Slides (Sigma Aldrich) 
C. Reagents 
1. Purified washed erythrocytes type O+ (Blood bank) 
2. Human blood AB+ serum (Blood bank) 
3. RPMI (Invitrogen) 
4. Albumax II (Invitrogen) 
 29 
5. Hypoxanthine (ccpro) 
6. Gentamicin (Invitrogen) 
7. Giemsa solution (Merck) 
8. NaCl (VWR Prolabo) 
9. Sorbitol (Fluka Biochemika) 
10. Glycerol (Roth) 
11. Giemsa solution (Merck) 
12. Cell culture water 
13. Tris base () 
14. HCl (Sigma Aldrich) 
15. 0.5M EDTA (Acros organics) 
16. DMSO (Grüssing Diagnostik analytika) 
17. Saponin (Sigma Aldrich) 
18. Triton X-100 (Sigma Aldrich) 
19. SYBR Green I (Invitrogen) 
20. 1.2 µm syringe filters (Sartorius)  
21. PBS (Sigma Aldrich) 
22. E64 (trans-Epoxysuccinyl-L-leucylamido (4-guanidino) butane (Sigma Aldrich)  
23. Paraformaldehyde (Applichem) 
24. Gluteraldehyde (Sigma Aldrich) 
25. Triton X (Sigma Aldrich) 
26. Blocking Aid Solution (Invitrogen)  
27. Alexa 546 (Invitrogen) 
 30 
28. Alexa 488 (Invitrogen) 
29. 2nd antibody in Blocking Aid (Invitrogen) 
30. Hoechst 33342 (Invitrogen) 
31. Nail Polish (essence color and go) 
32. Trizol LS Reagent (Invitrogen) 
33. Chloroform (Sigma Aldrich) 
34. pure Link RNA Mini Kit (Invitrogen) 
35. 2 - mercaptoethanol (Sigma Aldrich) 
36. DNAse I amplification grade (Invitrogen) 
37. Superscript II reverse transcriptase (Invitrogen)  
38. Agarose (Invitrogen) 
39. Ladders (Invitrogen) 
40. DNA Loading Dye (Ambion) 
Methods 
Cell Culture 
 
Plasmodium falciparum lab strain 3D7 was cultured in vitro according to the protocol 
by Trager and Jensen (1976). Briefly, P. falciparum was cultured in Human O+ 
erythrocytes at 5% haematocrit in culture media containing RPMI 1640 (Invitrogen) 
supplemented with L glutamine and HEPES, 10% Albumax II (Invitrogen), 2% 
Human AB+ serum, 1% Hypoxanthine (ccpro) and 0.05% Gentamicin (Invitrogen) in 
92% N2, 5% CO2, 3% O2 . Parasite growth was then followed by examination and 
counting parasitemia using giemsa stained thin smears. 
In vitro drug sensitivity assay and classical delayed death assay 
 
Stock drug solutions of Clindamycin hydrochloride (Sigma Aldrich),  Chloroquine 
(Sigma Aldrich) and Fosmidomycin (Sigma Aldrich), were prepared in dimethyl 
sulfoxide (DMSO) and in water respectively. Working solutions were then prepared in 
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incomplete culture media containing only RPMI 1640 (Invitrogen) supplemented with 
L glutamine and HEPES, 1% Hypoxanthine (ccpro) and 0.05% Gentamicin 
(Invitrogen). One hundred microliters of incomplete culture media was then added 
into 96 wells culture plate. Into this, 100 µl of P. falciparum cultures synchronized 
with 5% D-Sorbitol (Lambros and Vanderberg 1979) and diluted to 2% hematocrit 
and 0.1% parasitemia was then added. Drugs were later added in a threefold dilution 
in quadruplicates. The cultures were then incubated at 37°C in 92% N2, 5% CO2, 3% 
O2   for 48, 72, 96 and 120 hours. Parasite growth was then determined by SYBR 
green assay (Smilkstein et al., 2004). IC50 was calculated using Excel sheets 
(Microsoft Office for mac 2011) (Figure 6 below, and Figure 18 under results). 
To determine effects of clindamycin exposure after invasion (the so called delayed 
death assay) (Figure 4 below), P. falciparum cultures were tightly synchronized with 
D-Sorbitol (Lambros and Vanderberg 1979). Then ring stages of the parasites which 
were about 6 hours old post invasion, were used to initiate different cultures. These 
were then treated with IC99 concentrations of either of the following drugs: 
• 50 nM clindamycin  
• 128.7 µM Fosmidomycin  
One group of the culture was was used to set up a negative control in which the 
parasites were only treated with DMSO. Growth and development of the cultures was 
then followed by examination using giemsa stained thin smears and light microscopy 
for two cycles. 
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Figure 4 Experimental set up to determine clindamycin half maximum inhibitory concentrations and effects of 
clindamycin exposure after invasion. Synchronised parasite cultures were treated with clindamycin at 6 hours post invasion. 
To assay clindamycin half maximum inhibitory concentrations parasite growth was then assayed by SYBR green assay 
(fluoresence detection assay) at 78, 102 and 126 hours post invasion. To assay effects of clindamycin exposure after invasion 
parasite growth was then determined by light microscopy at 12 hours intervals until 108 post invasion.  
In vitro Clindamycin Exposure Before Invasion 
 
To determine effects of clindamycin exposure before invasion (Figure 5 below; 
Synchornisation of drug pressure and parasite cycle); briefly, merozoites were 
isolated according to the protocol by Boyle et al., (2010 B) and exposed to 
clindamycin before invasion (Figure 5 below). This was done by first tightly 
synchronizing P. falciparum cultures with D-Sorbitol (Lambros and Vanderberg 1979) 
and heparin (Boyle et al., 2010 A and B). Then after 40 - 42 hours post invasion the 
cultures were treated with E64 (Sigma Aldrich) and incubated for 5-8 hours. The 
cultures were then filtered in incomplete culture media through 1.2 µm syringe filters 
(Sartorius). Equal portions of the merozoites filtrate were used to initiate different 
cultures that were treated before invasion with 50nM clindamycin. A portion of the 
filtrate was used to set up a negative control in which the merozoites were not 
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exposed to any drug treatment and a positive control in which the merozoites were 
initially not exposed to any drug treatment but after 6 hours pot invasion the cultures 
were treated with 50 nM clindamycin. Growth and development of the cultures was 
then followed by examination using giemsa stained thin smears and light microscopy 
for two cycles. 
 
 
Figure 5 Experimental set up to synchronise clindamycin drug pressure and parasite cycle. P. falciparum was cultured in 
vitro and tightly synchronised. Merozoites were then isolated and exposed to clindamycin before invasion. The cultures were 
then followed for two cycles by assaying parasites growth and development using light microscopy. 
Determination of the effect of synchronising clindamycin drug pressure and 
parasite cycle on the Apicoplast biogenesis  
 
The effect of synchronising clindamycin drug pressure and parasite cycle on the 
apicoplast biogenesis (Figure 6 below) was determined using immunofluorescence 
assay (IFA) as described by Tonkin et al., (2004). Briefly, different groups of cultures 
were exposed to clindamycin before invasion as described above. Then cells were 
harvested from these cultures after every 12 hours for 2 cycles (Figure 6 below). 
They were then washed with 1X PBS and fixed using 4% Paraformaldehyde 
(AppliChem) and 0.75% Gluteraldehyde (Sigma Aldrich) in 1X PBS for 30 minutes at 
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37°C. After fixation, they were washed with 1x PBS and thin smears were made on 
Poly - L - Slides (Sigma Aldrich). Permeabilization was then done by treating them 
with 0.2% Triton X-100 (Carl Roth) in 1X PBS for 30 minutes at room temperature. 
They were washed with 1X PBS and blocked by treating them with Blocking Aid 
Solution (BAS) (Invitrogen) for 1 hour at room temperature in a humidified chamber. 
Anti-ACP primary antibodies diluted 1:250 in Blocking Aid Solution (Invitrogen) were 
then applied. The cells were then incubated for 1-2 hours in a dark humidified 
chamber at room temperature. They were then washed three times in 1X PBS and 
then secondary antibodies; Alexa Fluor 546 (Invitrogen) diluted 1:1000 in Blocking 
Aid Solution (Invitrogen) were applied. They were then incubated for 1 hour in a dark 
humidified chamber at room temperature and then washed three times in 1X PBS. 
Hoechst 33342 (Invitrogen) diluted 1:1000 in 1x PBS was then added and the cells 
were incubated for 5 minutes in a humidified dark chamber at room temperature. 
They were then washed three times in 1X PBS. Finally, they were mounted with Pro-
long Gold mounting solution (Invitrogen) and examined with a fluorescence 
microscope (Zeiss Observer.Z1). 
 
 
Figure 6 Experimental set up to determine the effect of synchronised clindamycin drug pressure and parasite cycle on 
the apicoplast biogenesis in P. falciparum. P. falciparum was cultured in vitro and tightly synchronised. Merozoites were then 
isolated and exposed to clindamycin before invasion. Apicoplast biogenesis was then assayed using immunofluorescence 
assay and fluoresence microscopy for two cycles.  
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Rescue Of Clindamycin Arrested Schizonts With Isopentenyl Pyrophosphate  
 
Rescue of clindamycin-arrested schizonts with isopentenyl pyrophosphate (Figure 7 
below), was done according to the protocol by Yeh and DeRisi (2011). Briefly, 
different groups of cultures were first exposed to clindamycin before invasion as 
described above. They were subsequently treated by adding 200 µM of IPP (Sigma 
Aldrich) at different time points post invasion, namely at 48, 60, 72, 84 and 96 hours. 
As controls, one group of cultures exposed to clindamycin before invasion and the 
negative control were not treated with IPP. 
 
 
Figure 7 Experimental set up to rescue clindamycin treated parasites with IPP. P. falciparum was cultured in vitro and 
tightly synchronised. Merozoites were then isolated and exposed to clindamycin before invasion. Then in different groups, 
apicoplast´s function was complemented by providing clindamycin treated parasites with IPP at different time points (at 48, 60, 
72, 78, 84 and 96 hours post invasion). As a negative control, one group was neither treated with clindamycin nor with IPP 
(Untreated). And as a positive control; one group was treated only with clindamycin and then only with water (Clindamycin). 
Parasite growth was then monitored at the beginning of the third cycle by assaying for ring stages of the parasites, which are 
indicators of a new cycle. 
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Induction of Egress with Zaprinast 
 
Induction of Egress in clindamycin-arrested schizonts with zaprinast (Figure 8) was 
done according to the protocol of Collins et al., (2013). Briefly, different groups of 
cultures were exposed to clindamycin before invasion as described above. They 
were subsequently treated by adding 100 µM of Zaprinast (Sigma Aldrich) at different 
times post invasion, namely: at 48, 60, 72, 84 and 95 hours. As controls, one group 
of cultures exposed to clindamycin before invasion and the negative control were not 
treated with zaprinast. 
 
 
 
Figure 8 Experimental set up to determine rescue of clindamycin treated parasites with zaprinast. P. falciparum was 
cultured in vitro and tightly synchronised. Merozoites were then isolated and exposed to clindamycin before invasion. Then in 
different groups, the parasite cultures were treated with  zaprinast in different groups and at different time points (48, 60, 72, 78, 
84 and 96 hours post invasion). As a negative control, one group was neither treated with clindamycin nor with zaprinast. And 
as a positive control; one group was treated only with clindamycin and then only with DMSO. Parasite growth was then 
monitored at the beginning of the third cycle by assaying for ring stages of the parasites, which are indicators of a new cycle. 
Mechanical rupture of clindamycin-arrested schizonts  
 
Mechanical rupture of clindamycin-arrested schizonts (Figure 9 below) was done by 
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first synchronizing drug pressure and parasite cycle as described above. Then 
towards the end of the 2nd cycle merozoites were isolated as described above. 
These were used to initiate new cultures. Parasite growth was then monitored at the 
beginning of the third cycle. 
 
 
 
Figure 9 Experimental set up to mechanically induce egress of clindamycin arrested schizonts. P. falciparum was 
cultured in vitro and tightly synchronised. Merozoites were then isolated and exposed to clindamycin before invasion. Then 
towards the end of the second cycle, merozoites were then isolated and used to initiate new cultures. Growth of the cultures 
was then determined by assaying for ring stages of the parasites at the beginning of the third cycle, which are indicators of new 
cycle.  
Determination Of The Effects Of Clindamycin-Induced Inhibition Of The 
Apicoplast Biogenesis On Pfsub1 Expression 
 
The effect of clindamycin-induced inhibition of the apicoplast biogenesis on PfSUB1 
expression (Figure 10 below), was determined using reverse transcriptase PCR 
according to the protocol by Sanyal et al., (2013). Briefly, different groups of cultures 
were exposed to clindamycin before invasion as described above. Then schizonts 
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were harvested by magnetic purification at the end of the second cycle. From these 
samples, total RNA was then isolated using pure Link RNA Mini Kit (Ambion) 
according to the manufacturers instructions. Potential DNA contaminants were 
eliminated by treating the samples with DNAse (Invitrogen) according to the 
manufacturers protocol. The product from this reaction was used as a template for 
complementary DNA (cDNA) synthesis. This was performed using superscript II 
reverse transcriptase (Invitrogen) according to the manufacturers instructions. 
Finally, lack of DNA contamination was confirmed by PCR (Table 2 below) with the 
primer pair 1 (Table 1 below) followed by DNA quantification using agarose gel 
electrophoresis (Supplementary figure 1). Real time PCR was then performed under 
the following conditions (Table 2) with the primer pairs 2 and 3 (Table 1). 
 
 
 
Figure 10 Experimental set up to determine the effects of clindamycin-induced inhibition of the apicoplast biogenesis 
on PfSUB1 expression. P. falciparum was cultured in vitro and tightly synchronised. Merozoites were then isolated and 
exposed to clindamycin before invasion. Samples were harvested towards the end of the 2nd cycle. Then gene expression 
analysis was done using real time PCR. 	
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Table 1 Primers  
 
Table 2 PCR conditions used to confirm lack of DNA contamination  
 
Table 3 RT PCR conditions 
 
Determination of The Effects Of Clindamycin-Induced Inhibition Of The 
Apicoplast Biogenesis On Secretion Of Pfsub1 
 
The effect of clindamycin-induced inhibition of the apicoplast biogenesis on secretion 
of Pfsub1 (Figure 11 below), was determined using immunofluorescence assay (IFA) 
according to the protocol by Collins et al., (2013). Briefly, different groups of cultures 
were exposed to clindamycin before invasion as described above. Then cells were 
harvested from these cultures towards the end of the second cycle. They were then 
washed with 1X PBS and fixed using 4% Paraformaldehyde (Agar Scientific) and 
0.0075% Gluteraldehyde (Sigma Aldrich) in 1X PBS for 30 minutes at room 
 40 
temperature. After fixation, they were washed with 1x PBS and thin smears were 
made on Poly - L - Slides (Sigma Aldrich). Permeabilization was done by treating 
them with 0.1% Triton X-100 (Carl Roth) in 1X PBS for 10 minutes at room 
temperature. They were washed with 1X PBS and blocked by treating them with 
Bovine Serum Albumin (BSA) (Roth) for 1 hour at room temperature in a humidified 
chamber. Anti-PfSUB1 as primary antibodies diluted 1:250 in PBS (Sigma Aldrich) 
/0.5% (v/v) Tween 20 (Sigma Aldrich) /1% (w/v) BSA (Roth) were then applied. The 
cells were then incubated for 1-2 hours in a dark humidified chamber at room 
temperature. They were then washed three times in 1X PBS and then the secondary 
antibodies (Alexa Flour 548 (Invitrogen)) diluted 1:1000 in PBS (Sigma Aldrich) /0.5% 
(v/v) Tween 20 (Sigma Aldrich) /1% (w/v) BSA (Roth) were then applied. The cells 
were then incubated for 1 hour in a dark humidified chamber at room temperature 
and then washed three times with 1X PBS. Hoechst 33342 (Invitrogen) diluted 
1:1000 in 1x PBS was then added and the cells were incubated for 5 minutes in a 
dark humidified chamber at room temperature. They were then washed three times 
with 1X PBS. Finally, they were mounted with Pro-long Gold mounting solution 
(Invitrogen) and examined on a fluorescence microscope (Zeiss Observer.Z1). 
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Figure 11 Experimental set up to determine the effect of clindamycin induced inhibition of the apicoplast function on 
PfSUB1 secretion in P. falciparum. P. falciparum was cultured in vitro and tightly synchronised. Merozoites were then isolated 
and exposed to clindamycin before invasion. PfSUB1 localisation was then assayed using immunofluorescence assay and 
fluoresence microscopy for two cycles.  
Determination of The Effects Of Clindamycin-Induced Inhibition Of The 
Apicoplast Biogenesis On Ca2+ Signalling 
 
The effects of clindamycin-induced inhibition of the apicoplast biogenesis on Ca2+ 
signalling (Figure 12 below), was determined according to the protocol by Agarwal et 
al., (2013). Briefly, different groups of cultures were exposed to clindamycin before 
invasion as described above. Towards the end of the second cycle the cultures were 
treated with 0.1 µM Fluo - 4AM (Invitrogen) and incubated for 20 minutes at 37° C. 
They were then washed 4 times by changing the media and centrifugation at 4000 X 
g for 3 minutes. The pellets were then re suspended with 3 ml incomplete culture 
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media and then the mean fluorescence intensity (MFI) was acquired using a FACS 
machine under the following settings: FSC - 66, SSC - 192, FITC - 418 and 50,000 
events. 
 
 
Figure 12 Experimental set up to determine effects of clindamycin induced inhibition of the apicoplast function on 
calcium signalling. P. falciparum was cultured in vitro and tightly synchronised. Merozoites were then isolated and exposed to 
clindamycin before invasion. Levels of intracellular Ca2+ were then assayed towards the end of the second cycle using flow 
cytometry. 
Determination of The Effect Of Clindamycin-Induced Inhibition Of The 
Apicoplast Biogenesis On Phosphoinositides Metabolism 
 
The effect of clindamycin-induced inhibition of the apicoplast biogenesis on 
phosphoinositides metabolism, was done as summarized in Figure 13 below. Briefly, 
different groups of cultures were exposed to clindamycin before invasion as 
described above. Then towards the end of the second cycle the samples were 
processed and phosphoinositide was measured using phosphatidylinositol 3 
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phosphate (PI(3)P) mass elisa kit  (echelon biosciences) and phosphatidylinositol 4 
phosphate (PI(4)P) mass strip kit (echelon biosciences) according to the 
manufacturers protocols. 
 
 
 
Figure 13 Experimental set up to determine effects of clindamycin induced inhibition of the apicoplast function on 
phosphoinositide metabolism. P. falciparum was cultured in vitro and tightly synchronised. Merozoites were then isolated and 
exposed to clindamycin before invasion. Levels of phosphoinositides; phosphatidylinositol 3 phosphate (PI3P) and 
phosphatidylinositol 4 phosphate (PI4P), were then assayed towards the end of the second cycle using flow cytometry and 
mass strips or mass elisa kits respectively. 
Determination of ADEPS In vitro activity against Plasmodium falciparum  
 
In vitro activity of ADEPS against Plasmodium falciparum was determined as 
summarized in Figure 14 below. Briefly, P. falciparum was cultured in vitro, tightly 
synchronized with D-Sorbitol according to the protocols by Lambros and Vanderberg 
(1979) and heparin by Boyle et al., (2010 A and B). Then after 40 - 42 hours post 
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invasion the cultures were treated with E64 (Sigma Aldrich) and incubated for 5-8 
hours. The cultures were then filtered in incomplete culture medium through 1.2 µm 
syringe filters (Sartorius) according to the protocol by Boyle et al., (2010 B). Equal 
portions of the merozoites filtrate were used to initiate different cultures that were 
treated before invasion with either of the following drugs: 
• ADEP 1 at 10 µg/ml and 30µg/ml 
• ADEP 4 at 10 µg/ml and 30µg/ml 
A portion of the filtrate was utilised to set up a negative control in which the 
merozoites were not exposed to any drug treatment. Growth and development of the 
cultures was then followed by examination using giemsa stained thin smears and 
light microscopy for two cycles. 
 
 
 
Figure 14 Experimental set up to determine in vitro activity of ADEPS against P. falciparum. P. falciparum was cultured in 
vitro and tightly synchronised. Merozoites were then isolated and exposed to ADEP1 or 4 before invasion. The cultures were 
then followed for two cycles by assaying parasites growth and development using light microscopy.	
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Determination of the effects of ADEP4 on apicoplast biogenesis  
 
The effect of ADEP4 on apicoplast biogenesis, was determined (Figure 15 below) 
using immunofluorescence assay (IFA) as described by Tonkin et al., (2004). Briefly, 
different groups of cultures were exposed to clindamycin before invasion as 
described above. Then cells were harvested from these cultures towards the end of 
the first and second cycles (Figure 15 below). They were then washed with 1X PBS 
and fixed using 4% Paraformaldehyde (AppliChem) and 0.75% Gluteraldehyde 
(Sigma Aldrich) in 1X PBS for 30 minutes at 37°C. After fixation, the cells were 
washed with 1x PBS and thin smears were made on Poly - L - Slides (Sigma 
Aldrich). Permeabilization was done by treating them with 0.2% Triton X-100 (Carl 
Roth) in 1X PBS for 30 minutes at room temperature. They were washed with 1X 
PBS and blocked by treating them with Blocking Aid Solution (BAS) (Invitrogen) for 1 
hour at room temperature in a humidified chamber. Anti-ACP primary antibodies 
diluted 1:250 in Blocking Aid Solution (Invitrogen) were then applied. The cells were 
then incubated for 1-2 hours in a dark humidified chamber at room temperature. They 
were then washed three times with 1X PBS and then secondary antibodies; Alexa 
Fluor 546 (Invitrogen), diluted 1:1000 in Blocking Aid Solution (Invitrogen) were 
applied. The cells were then incubated for 1 hour in a dark humidified chamber at 
room temperature and then washed three times in 1X PBS. Hoechst 33342 
(Invitrogen) diluted 1:1000 with 1x PBS was then added and they were incubated for 
5 minutes in a dark humidified chamber at room temperature. They were then 
washed three times with 1X PBS. Finally, they were mounted with Pro-long Gold 
mounting solution (Invitrogen) and examined with a fluorescence microscope (Zeiss 
Observer.Z1). 
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Figure 15 Experimental set up to determine effects of ADEP4 on apicoplast biogenesis in P. falciparum. P. falciparum 
was cultured in vitro and tightly synchronised. Merozoites were then isolated and exposed to ADEPS 1 or 4 before invasion. 
Apicoplast biogenesis was then assayed using immunoflourescence assay and fluoresence microscopy towards the end of the 
first and second cycle. 
 
Determination of the effects of ADEP4 on apicoplast function  
 
To determine effect of ADEP4 on apicoplast function (Figure 16 below); different 
groups of cultures were first exposed to ADEPS before invasion as described above. 
They were then treated by adding 200 µM of IPP (Sigma Aldrich) at 48 hours post 
invasion. As controls, one group of cultures exposed to ADEPS before invasion and 
the negative control were not treated with IPP. 
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Figure 16 Experimental set up to determine effect of ADEP4 on apicoplast function. P. falciparum was cultured in vitro 
and tightly synchronised. Merozoites were then isolated and exposed to ADEP4 before invasion. The cultures were then 
maintained under continuous exogenous IPP provision and followed for two cycles by assaying parasites growth and 
development using light microscopy. 
Chemical Knock - Out of the apicoplast 
 
Chemical knock-out of the apicoplast (Figure 17 below) was performed according to 
the protocol by Yeh and DeRisi (2011). Briefly, merozoites were isolated as 
described above, they were then treated with 50nM clindamycin before invasion and 
used to initiate cultures. Starting at 48 hours post invasion the cultures were treated 
by adding 200 µM of IPP (Sigma Aldrich). Then after 48 hours, the culture media was 
replaced with fresh media and IPP. As controls, one group of cultures exposed to 
clindamycin before invasion and the negative control were not treated with IPP. 
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Figure 17 Experimental set up to determine whether the apicoplast is the target for ADEPS. P. falciparum was cultured in 
vitro and tightly synchronised. Merozoites were then isolated and exposed to clindamycin before invasion. Starting at 48 hours 
post invasion, the cultures were then maintained under continuous exogenous IPP provision for several cycles. The parasites 
were subsequently treated with ADEP4, maintained under continuous exogenous IPP provision and followed for two cycles by 
assaying parasites growth and development using light microscopy. 
Data Analysis 
 
Graphs for medians, means and standard deviations of treatment groups were 
generated using excel (Microsoft office 2010 for macs). Data analysis was performed 
using Stata® (Version 12.1 Statacorp USA). This was done by comparing the 
medians or means from the different treatment groups using the Kruskal-wallis rank 
test and a P value of 0.05.  
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RESULTS 
Part 1 
Clindamycin causes an egress defect of P. falciparum  
 
In order to solve the puzzle regarding the discrepancy in the response of P. 
falciparum to clindamycin during its liver and blood stages, this study mimicked the 
experimental set up in the liver stage studies by Friesen et al., (2010).  To begin with, 
P. falciparum blood stage was cultured in vitro. Then its sensitivity to clindamycin 
was determined by growth inhibitory assay on exposure post invasion (Figure 4). As 
compared to chloroquine and fosmidomycin, the parasite sensitivity to clindamycin 
increased with time (Figure 18 and 19 below). This is a classical phenotype termed 
delayed death (Surolia et al., 2004; Burkhardt et al., 2007; Dahl and Rosenthal 2007; 
Goodman et al., 2007). This confirmed that the drug that was utilized was working. 
 
 
 
Figure 18 Half maximum inhibitory concentration values (IC50) of clindamycin. P. falciparum was treated with clindamycin 
6 hours post invasion. Parasite gowth was then determined after 72, 96 and 120 hours post invasion. Chloroquine and 
fosmidomycin were used as control drugs. Note that the parasites only become sensitive to clindamycin after two cycles as 
opposed to one cycle under chloroquine or fosmidomycin. For clindamycin the IC50 values were 15, 48 nM/L and 113,647 nM/L 
at 126, 102 and 78 hours post-invasion respectively. For chloroquine the IC50 values were 7,8 and 9 nM/L at 126, 102 and 78 
hours post-invasion respectively. For fosmidomycin the IC50 values were 716, 524 and 2249 nM/L at 126, 102 and 78 hours 
post-invasion respectively. 
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Figure 19 Growth inhibitions of P. falciparum treated with clindamycin 6 hours post invasion. Note the arrest of 
clindamycin treated parasites during the second cycle as opposed to the first cycle in fosmidomycin treated parasites. Error bars 
represent standard deviation of the mean. 
 
In order to study the effects of synchronized antibiotic drug pressure and parasite 
cycle during the blood stage (Figure 5 under materials and methods section), P. 
falciparum was cultured in vitro in human erythrocytes. These cultures were then 
tightly synchronised using D-Sorbitol, heparin and magnetic columns as described in 
materials and methods. From a population of schizonts only, merozoites were then 
isolated and exposed to clindamycin before invasion. Parasite growth was 
subsequently monitored for 2 cycles by light microscopy. 
During the first cycle, there was no growth inhibition in both the treated and untreated  
parasite cultures (Figure 20). In both cases, parasites managed to egress from the 
erythrocytes, invaded uninfected erythrocytes, initiating a second cycle. During this 
second cycle, they both transformed into rings, trophozoites and schizonts. The 
untreated parasites were yet again able to egress and invade uninfected 
erythrocytes. However, the treated parasites were arrested towards the end of the 
second cycle as segmented schizonts (Figure 21). This indicated that clindamycin 
induces an egress defect.  
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Figure 20 Growth inhibition of P. falciparum on treatment with clindamycin before invasion. Note the arrest during the 
second cycle of parasites treated with clindamycin before invasion (Test) or post invasion (Positive control). Error bars represent 
standard deviation of the median. 
 
 
 
Figure 21 Thin smears of P. falciparum in vitro cultures during the second cycle post invasion. The bottom row 
represents parasites treated with clindamycin and the top row is the control. Note the arrested schizonts towards the end of the 
second cycle and beginning of the third cycle in clindamycin treated parasites (Clindamycin Hour 84 - 96).  
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Inhibition of egress correlates with inhibition of the apicoplast biogenesis. 
 
The antimalarial effect of clindamycin is based on the inhibition of the apicoplast 
biogenesis and inheritance (Camps et al., 2002; Goodman et al., 2007; Friesen et al., 
2010). Therefore in order to determine the fate of the apicoplast under synchronized 
drug exposure and parasite cycle, the biogenesis of the apicoplast was assayed by 
immunofluorescence assay and fluorescence microscopy (Figure 6 under materials 
and methods section).  
During the first cycle, in both the treated and untreated cultures, the organelle grew, 
branched and got segregated into daughter cells (Figure  22 and 23), which were 
able to egress and invade uninfected erythrocytes. Towards the end of the second 
cycle, the organelle in the control was able to grow, branch and got segregated to 
daughter cells (Figure 24 and 25). These were then able to egress and invaded 
uninfected erythrocytes. In contrast, the clindamycin-arrested schizonts displayed a 
stunted apicoplast that was not able to grow, branch and segregate (Figure 24 and 
25). This indicated that the inhibition of the apicoplast biogenesis and function 
preceded the inhibition of egress.  
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Figure 22 Effects of clindamycin on the apicoplast biogenesis in P. falciparum during the first half of the first cycle. 
Shown here are immunofluorescence assay pictures of the apicoplast of P. falciparum treated with clindamycin before (Test) or 
6 hours after invasion (Positive control) as compared to untreated cultures (Negative control). In the first half of the cycle (Hour 
12-21), there was no inhibition of apicoplast biogenesis in the treated and untreated cultures. Key: DIC: Cells, Apicoplast: 
apicoplast anti-ACP primary antibodies stained with Alexa 546 secondary antibodies, DNA: Nucleus stained with Hoeschst, 
Merge: Combination of Alexa 546 and Hoeschst. 
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Figure 23 Effects of clindamycin on the apicoplast biogenesis in P. falciparum during the second half of the first cycle. 
Shown here are immunofluorescence assay pictures of the apicoplast of P. falciparum treated with clindamycin before (Test) or 
6 hours after invasion (Positive control) as compared to untreated cultures (Negative control). In the second half of the first cycle 
(Hour 36-42), there was again no inhibition of apicoplast biogenesis in the the treated and untreated cultures. Key: DIC: Cells, 
Apicoplast: apicoplast anti-ACP primary antibodies stained with Alexa 546 secondary antibodies, DNA: Nucleus stained with 
Hoeschst, Merge: Combination of Alexa 546 and Hoeschst. 
 55 
 
 
 
 
Figure 24 Effects of clindamycin on the apicoplast biogenesis in P. falciparum during the first half of the second cycle. 
Shown here are immunofluorescence assay pictures of the apicoplast of P. falciparum treated with clindamycin before (Test) or 
6 hours after invasion (Positive control) as compared to untreated cultures (Negative control). In the first half of the second cycle 
(Hour 60-66), there was again no inhibition of apicoplast biogenesis in the treated and untreated cultures. Key: DIC: Cells, 
Apicoplast: apicoplast anti-ACP primary antibodies stained with Alexa 546 secondary antibodies, DNA: Nucleus stained with 
Hoeschst, Merge: Combination of Alexa 546 and Hoeschst. 
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Figure 25 Effects of clindamycin on the apicoplast biogenesis in P. falciparum during the second half of the second 
cycle. Shown here are immunofluorescence assay pictures of the apicoplast of P. falciparum treated with clindamycin before 
(Test) or 6 hours after invasion (Positive control) as compared to untreated cultures (Negative control). Towards the end of the 
second cycle (Hour 84-90), there was again no inhibition of apicoplast biogenesis in the untreated cultures, but in the treated 
cultures (before or after invasion) there was inhibition of apicoplast biogenesis. Key: DIC: Cells, Apicoplast: apicoplast anti-ACP 
primary antibodies stained with Alexa 546 secondary antibodies, DNA: Nucleus stained with Hoeschst, Merge: Combination of 
Alexa 546 and Hoeschst. 
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Chemical complementation of the apicoplast function reverses egress defects 
 
Antibiotic treated parasites can be rescued by provision of exogenous IPP (Ye and 
DeRisi 2011). Surprisingly, full rescue, however, was only achieved when IPP was 
supplemented at the beginning of the second cycle, i.e. 48 hours pre-egress (Ye and 
DeRisi 2011). To circumvent the clindamycin induced inhibition of the apicoplast´s 
biogenesis and function (Figures 22 - 25) and inhibition of the parasite egress (Figure 
21), clindamycin-treated parasites were supplemented with IPP at 12 hours intervals 
in different groups starting at 48 hours post-invasion (Figure 7 under materials and 
methods section). 
Because the function of the apicoplast during the blood stage is to produce IPP, 
therefore, ideally rescue with IPP should have been possible for all the tested time 
points. However, the arrested schizonts were able to transform into rings but in a 
proportion dependent on the time point of IPP provision (Figure 26). Such that only 
IPP treatment done at the time points away from egress (Hour 48, 60, 72 and 78) 
was able to rescue the parasites. But IPP treatment done at the time points close to 
egress (Hours 84) did not rescue the parasites. This indicated that the egress 
inhibition (Figure 21 above) is due to the clindamycin-induced shortage of IPP and 
that a factor or process that is needed to enable the parasites to egress depends on 
IPP. This factor or process starts to function early during the cycle. Therefore 
supplementation with IPP needs to be done early in the cycle as well. 
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Figure 26 IPP rescue of clindamycin treated parasites at different time points post invasion. Only provision of IPP for the 
time points close to invasion was able to rescue the parasites (TR H48, TR H60, TR H72 and TR H78) but time points close to 
egress (TR84 and TR96) did not rescue the parasites. Key: TR48, TR60, TR72, TR78, TR84 and TR96: Test sample treated 
with IPP at 48, 60, 72, 78, 84 and 96 hours post invasion respectively. Error bars represent standard deviation of the median. 
Zaprinast induces egress of Clindamycin-arrested schizonts 
 
Since IPP provision could not directly rescue the egress defects, chemical and 
mechanical means were applied to induce egress. To start with, the chemical means 
were used (Figure 8 above, under materials and methods section). Egress of P. 
falciparum involves the activation of Protein Kinase G (PKG) by a natural egress 
signal (Collins et al., 2013) which can be mimicked by zaprinast. PKG, in-turn 
activates egress of P. falciparum (Collins et al., 2013). Therefore, to induce egress of 
the clindamycin-arrested schizonts, they were treated with zaprinast at 12 hours 
intervals in different groups starting at 48 hours post-invasion.  
 
As an artificial trigger of egress, zaprinast (Collins et al, 2013), would be expected to 
result in inducing rupturing of schizonts. In cultures not treated with clindamycin, 
according to light microscopy, zaprinast indeed induced premature egress (data not 
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shown) and this resulted in successful invasion (Figure 27). However, as compared 
to the untreated parasites, in clindamycin treated parasites zaprinast rescue did not 
work as expected. It induced an unusual early rescue, where, only parasites treated 
with zaprinast; immediately, after invasion were able to progress to a 3rd cycle 
(Figure 28). And according to light microscopy, clindamycin arrested schizonts did 
not rupture when treated with zaprinast towards egress (data not shown). This 
means that; only early treatment with zaprinast, can reverse clindamycin effects. And 
since this observation is reminiscent of; only early IPP provision also, being able to 
rescue the parasites (Figure 26). This suggests that; egress machinery starts getting 
stimulated or assembled at the beginning of the cycle. 
 
Figure 27 Effect of zaprinast on Plasmodium falciparum. As compared to the control, culture treated with zaprinast at 43 
hours post invasion i.e. towards the end of the second cycle, were still able to progress to a third cycle. 
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Figure 28 Zaprinast rescue of clindamycin arrested schizonts at different time points post invasion. Treatment of 
clindamycin arrested schizonts with Zaprinast at 48 hours post invasion was able to rescue the parasites. Key: ZH48, ZH60, 
ZH72, ZH84 and ZH95: Test samples treated with clindamycin before invasion and then with Zaprinast at 48, 60, 72, 84 or 95 
hours post invasion. P values represent Kruskal wallis rank test of the medians and error bars represents standard deviation of 
the median. 
 
Mechanically released merozoites from clindamycin-arrested schizonts are 
non-invasive  
 
The ability of merozoites to egress is a prerequisite to invasion (Collins et al., 2013). 
PKG and calcium dependent protein kinase 5 (CDPK5) regulate the egress pathway 
(Dvorin et al., 2010). In addition PKG also regulates invasion (Alam et al., 2015). 
Mechanical rupture of arrested schizonts due to inhibition of these proteins has been 
used to investigate the egress pathway (Dvorin et al., 2010). Therefore, failure to 
induce egress by chemical means led to the attempt to circumvent the clindamycin-
induced block of the parasite egress by mechanical rupture of the arrested schizonts 
(Figure 9 above, under materials and methods section). 
These mechanically induced egress produced merozoites with normal morphology 
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(data not shown), indicating that the arrested merozoites are ready to egress but 
unable to. Therefore confirming the observed egress defect phenotype (Figure 21 
above). However, these mechanically-released-merozoites were unable to invade 
(Figure 29) indicating that they do not only have egress defects but also invasion 
defects. This is a phenotype similar to treatment with PKG inhibitors during egress 
(Dvorin et al., 2010) and invasion (Alam et al., 2015). Nonetheless, it is different to 
CDPK5 knock down (Dvorin et al., 2010). This suggested clindamycin inhibition of 
the apicoplast biogenesis and function inhibits the egress pathway.  
 
 
 
Figure 29 Invasion assay at 12 hours post invasion. As compared to the control, merozoites released by mechanical rupture 
of clindamycin arrested schizonts were not able to invade erythrocytes. P values represent Kruskal wallis rank test of the 
medians and error bars represents standard deviation of the median. 
Clindamycin-induced inhibition of the apicoplast does not inhibits expression 
of PfSUB1 
 
During egress, PKG functions to regulate the secretion of PfSUB1 (Collins et al., 
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2013) from exonemes into the parasitophorous vacuole (Yeoh et al., 2007). PfSUB1 
is a serine protease which links egress and invasion (Koussis et al. 2009). It 
mediates the activation of proteins required for egress, namely: serine like antigens 
(SERAs) (Collins et al., 2013) and P. falciparum perforin like proteins (PfPLPs) (Garg 
et al., 2013), as well as proteins required for invasion, namely; merozoite surface 
proteins 1, 6 and 7 (MSP1, 2 and 7) (Koussis et al. 2009). Clindamycin arrested 
schizonts; are neither able to naturally egress (Figure 21), nor upon chemical 
induction by treatment with zaprinast (Figure 28 above) or upon mechanical induction 
(Figure 29 above). In addition the merozoites from this schizonts are unable to 
invade (Figure 29 above). Therefore, expression and immunolocalization of PfSUB1 
was performed to determine whether these parasites are able to secret PfSUB1 from 
exonemes (Figures 10 and 11 above, under materials and methods section).  
Firstly, expression of PfSUB1 was determined by analysing the expression of 
Plasmodium falciparum subtilisin like serine protease-1 (Pfsub1, accession number 
PF3D7_0507500) and Arginine-tRNA ligase (Pfatl, accession number 
PF3D7_1218600) as a house keeping gene (Figure 10 above, under materials and 
methods section). There was no significant difference between the control and 
treated parasites in the expression of Pfsub1 and Pfatl  indicating that clindamycin 
arrested schizonts are indeed metabolic active (Figure 30 below).  
 
 
 
Figure 30 Assay of PfSUB1 expression. There was no significant differences in the expression of a house keeping gene 
(Pfatl) and a non-house keeping gene (Pfsub1) between the treated and untreated cultures. P values represent Kruskal wallis 
rank test of the medians and error bars represents standard deviation of the median. 
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Clindamycin-induced inhibition of the apicoplast inhibits secretion of PfSUB1 
 
Secondly, to determine whether clindamycin arrested schizonts are able to secrete 
PfSUB1 from exonemes, localization of PfSUB1 was determined by 
immunofluorescence assay and fluoresence microscopy at the end of the second 
cycle (Figure 11 above, under materials and methods section). 
Anti-PfSUB1 antibodies, indicated a signal ranging from absent, weak to diffuse in 
untreated cultures (Figure 31), a characteristic of secreted PfSUB1 (Collins et al., 
2013). However, treated cultures had strong and punctate signal (Figure 32) 
characteristic of unsecreted PfSUB1 (Collins et al., 2013). On early treatment with 
IPP, a product of the apicoplast function, the appearance of PfSUB1 signal ranged 
from weak to diffuse (Figure 33). This confirmed the function of the apicoplast in 
egress. On early treatment with zaprinast, it appeared strong and punctate in some 
cells and in other cells it appeared weak and diffused (Figure 34). This indicated that 
clindamycin-induced inhibition of the apicoplast biogenesis and function inhibits the 
secretion of PfSUB1, explaining why the merozoites in clindamycin arrested 
schizonts have egress and invasion defects (Figures 21 and 29). 
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Figures 31 Immunofluorescence assay of PfSUB1 at the end of the second cycle in untreated parasites. Shown here are 
immunofluorescence assay pictures of the localisation of PfSUB1 in untreated P. falciparum. In the various cells observed the 
appearance of PfSUB1 ranged from absent, weak to diffuse. Key: DIC: Cells, Anti-PfSUB1: anti-PfSUB1 primary antibodies 
stained with Alexa 588 secondary antibodies, DNA: Nucleus stained with Hoeschst, Merge: Combination of Alexa 548 and 
Hoeschst. 
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Figures 32 Immunofluorescence assay of PfSUB1 at the end of the second cycle in clindamycin treated parasites. 
Shown here are immunofluorescence assay pictures of the localisation of PfSUB1 in P. falciparum treated with clindamycin 
before invasion. In the various cells observed the appearance of PfSUB1 was mostly strong and punctated. Key: DIC: Cells, 
Anti-PfSUB1: anti-PfSUB1 primary antibodies stained with Alexa 588 secondary antibodies; DNA: Nucleus stained with 
Hoeschst; Merge: Combination of Alexa 548 and Hoeschst. 
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Figures 33 Immunofluorescence assay of PfSUB1 at the end of the second cycle in clindamycin treated parasites and 
rescued with IPP. Shown here are immunofluorescence assay pictures of the localisation of PfSUB1 in P. falciparum treated 
with clindamycin before invasion and then with IPP at 48 hours post invasion. The appearance of PfSUB1 ranged from weak to 
diffuse. Key: DIC: Cells, Anti-PfSUB1: anti-PfSUB1 primary antibodies stained with Alexa 588 secondary antibodies, DNA: 
Nucleus stained with Hoeschst, Merge: Combination of Alexa 548 and Hoeschst. 
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Figures 34 Immunofluorescence assay of PfSUB1 at the end of the second cycle in clindamycin treated parasites and 
rescued with zaprinast. Shown here are immunofluorescence assay pictures of the localisation of PfSUB1 in P. falciparum 
treated with clindamycin before invasion and then with zaprinast at 48 hours post invasion. The appearance of PfSUB1 was 
strong and punctate in some cells and in others it ranged from absent, weak to diffuse. Key: DIC: Cells, Anti-PfSUB1: anti-
PfSUB1 primary antibodies stained with Alexa 588 secondary antibodies, DNA: Nucleus stained with Hoeschst, Merge: 
Combination of Alexa 548 and Hoeschst. 
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Clindamycin-induced inhibition of the apicoplast does not inhibit calcium 
signaling and phosphoinositide metabolism 
 
PKG functions to regulate the secretion of PfSUB1 (Collins et al., 2013) from 
exonemes into the parasitophorous vacuole (Yeoh et al., 2007) by stimulating an 
increase in intracellular Ca2+ (Brochet et al., 2014). Increase in intracellular Ca2+ is 
required for egress of P. falciparum (Agarwal et al., 2013; Collins et al., 2013; 
Glushakova et al., 2013), this is because it functions to induce secretion of PfSUB1 
(Agarwal et al., 2013). Therefore in order to understand how clindamycin induced 
inhibition of the apicoplast biogenesis and functions (Figures 21 – 26 above) inhibits 
PfSUB1 secretion (Figures 31 – 34 above), calcium signalling was determined under 
clindamycin treatment. This was done by assaying the levels of intracellular Ca2+, 
towards the end of the second cycle (Figure 12 above, under materials and methods 
section).  
There was no significant difference in the levels of intracellular calcium ions in 
clindamycin treated parasites as compared to untreated parasites (Figures 35). Early 
rescue with IPP or zaprinast did not significantly change these levels (Figures 35). 
This indicated that clindamycin-induced inhibition of PfSUB1 secretion is not through 
the inhibition of calcium signalling.  
 
 
 69 
 
 
Figures 35 Levels of free intracellular calcium ion measured at the end of the second cycle. There was no significant 
difference in the levels of free intracellular calcium ions in clindamycin treated parasites (Treated) as compared to untreated 
parasites. Early rescue with IPP (Treated+ipp) did not significantly change these levels. Even though with a borderline 
significant P value, early rescue with zaprinast (Treated+zap H48) appeared to increase free intracellular calcium ions but not 
when applied towards the end of the cycle (Untreated+zap H88). Key: ipp; isopentenyl pyrophosphate, zap; Zaprinast, H48; 48 
hours post invasion, H88; 88 hours post invasion. P values represents Kruskal wallis rank test of the medians and error bars 
represents standard deviation of the median. 
 
Clindamycin-induced inhibition of the apicoplast does not inhibit 
phosphoinositide metabolism 
 
PKG functions to regulate the secretion of PfSUB1 (Collins et al., 2013) from 
exonemes into the parasitophorous vacuole (Yeoh et al., 2007), by regulating the 
hydrolysis of phosphatidylinositol 4,5 bisphosphate (PI4,5BP) to increase intracellular 
Ca2+ (Brochet et al., 2014). Increase in intracellular Ca2+ is required for egress of P. 
falciparum (Agarwal et al., 2013; Collins et al., 2013; Glushakova et al., 2013). 
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PfSUB1 secretion (Figures 31 – 34 above), phosphoinositide metabolism was 
determined under clindamycin treatment. This was done by assaying the levels of 
phosphatidylinositol 3 phosphate (PI3P) and phosphatidylinositol 4 phosphate (PI4P) 
towards the end of the second cycle (Figure 13 above, under materials and methods 
section).  
There was no significant difference in the levels of phosphoinositides in clindamycin 
treated parasites as compared to untreated parasites (Figures 36 and 37). In the 
case of PI4P, early rescue with IPP or zaprinast did not significantly change these 
levels (Figure 37). This indicated that clindamycin-induced inhibition of PfSUB1 
secretion is not through the inhibition of phosphoinositide metabolism.  
 
 
 
Figures 36 Levels of phosphatidylinositol 3 phosphate (PI3P) measured at the end of the second cycle. There was no 
significant difference in the levels of PI3P in clindamycin treated parasites (treated) as compared to untreated. P values 
represent Kruskal wallis rank test of the medians and error bars represent standard deviation of the median. 
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Figures 37 Levels of phosphatidylinositol 4 phosphate (PI4P) measured at the end of the second cycle. There was no 
significant difference in the levels of PI4P in clindamycin treated parasites (Treated) as compared to untreated parasites. Early 
rescue with IPP (Treated+IPP) or zaprinast (Treated+Zaprinast) did not significantly change these levels. P values represent 
Kruskal wallis rank test of the medians and error bars represent standard deviation of the median. 
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Part 2 
ADEP 4 slows down the cell cycle of Plasmodium falciparum 
 
ADEPS are new type of antibacterial drugs (Brötz - Oesterhelt et al., 2005; Sass et 
al., 2011). Therefore, to determine whether they can act as antimalarial drugs, P. 
falciparum was exposed in vitro to different types of ADEPS: ADEP 1 and 4 (Figure 
14 above, under materials and methods section).  
ADEP 1, demonstrated two different effects: As compared to untreated parasites, at 
high concentrations ADEP 1 inhibited parasite growth within 72 hours (Figure 38). 
But, at low concentrations, ADEP 1 did not show any activity against P. falciparum 
(Figure 38). ADEP 4, also demonstrated two different effects. However, as compared 
to untreated parasites, at high concentrations it inhibited parasite growth within the 
first 24 hours (Figure 39). But, at low concentrations, it induced slow parasite growth 
(Figures 39 and 40). Indicating that; ADEP4 was more active against P. falciparum 
than ADEP1.  
 
Figure 38 Growth inhibition assay of ADEP1 on P. falciparum. ADEP1 at 10 ug/ml (ADEP1-10) did not inhibit parasite 
growth while ADEP1 at 30 ug/ml (ADEP1-30), inhibited parasite growth around 72 hours during the second cycle. Key: H24, 
H48, H72 and H96 means 24, 48, 72 and 96 hours post invasion respectively. Error bars represent standard deviation of the 
median. 
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Figure 39 Growth inhibition assay of ADEP4 on P. falciparum. ADEP4 at 10 ug/ml (ADEP4-10) induced slow parasite 
growth while ADEP4 at 30 ug/ml (ADEP4-30), inhibited parasite growth within 24 hours during the first cycle. Key: H24, H48, 
H72 and H96 means 24, 48, 72 and 96 hours post invasion respectively. Error bars represent standard deviation of the median. 
 
  
 
Figure 40 Response of P. falciparum  to treatment with ADEP 4 at 10 µg/ml. Untreated merozoites were able to invade 
erythrocytes, transformed into rings, trophozoites (Untreated Hour 24) and then into schizonts (Untreated Hour 48). This in turn 
gave rise to merozoites that were able to invade uninfected erythrocytes and initiate a second cycle during which they again 
transformed into rings (Untreated Hour 48), trophozoites (Untreated Hour 72) and then into schizonts which later formed 
merozoites that started a new cycle (Untreated Hour 96). Merozoites treated with ADEP 4 at 10 µg/ml were able to form rings 
but became arrested (ADEP4 Hour 24) and transformed very late in the cycle into trophozoites (ADEP4 Hour 42), which 
remained arrested as trophozoites (ADEP4 Hour 48). This in turn gave rise to merozoites that were able to invade erythrocytes 
and initiate a second cycle very late (ADEP4 Hour 72), at a time point, where the untreated parasites are already in the middle 
of their second cycle (Untreated Hour 72). They finally transform into trophozoites very late in the cycle (ADEP4 Hour 96). 
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ADEP4 induces filamentation of the apicoplast 
 
The apicoplast is bacterial in nature (Wilson et al., 1996) and since it cannot be 
formed de novo it has to be inherited from the mother cell to the daughter cell. In 
order for this to happen it first undergoes biogenesis, whereby it starts as a tiny 
structure that grows, branches and eventually gets segregated to the daughter cells, 
which later egress and invade uninfected erythocytes (Waller and McFadden 2005). 
Since ADEP4 has inhibitory effects against P. falciparum (Figures 38 and 39), 
therefore in order to determine whether the apicoplast was its target, its biogenesis 
was studied using immunofluorescence assay at the end of the first and second cycle 
under treatment with ADEP 1 and 4 at 10 µg/ml (Figure 15 above, under materials 
and methods section).  
The apicoplast biogenesis under ADEP1 was not affected both during the end of the 
first and second cycle (Figures 41 A and B). However, under ADEP4 treatment, at 
the time point, where it should have undergone segregation i.e. at the end of the first 
and second cycle, it remained still branched (Figures 41 A and B). This morphology 
is typical of trophozoites, confirming that ADEP4 delays the parasite cycle during the 
blood stage and it does this, through inhibition of the apicoplast biogenesis. 
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Figure 41 Effects of ADEPS on the biogenesis of the apicoplast during the first (A) and second cycle (B). As compared 
to untreated parasites, ADEP1 had no effect on the apicoplast biogenesis. ADEP4 however inhibited the biogenesis of the 
apicoplast. Key: DIC: Cells, Apicoplast: apicoplast anti-ACP primary antibodies stained with Alexa 546 secondary antibodies; 
DNA: Nucleus stained with Hoeschst; Merge: Combination of Alexa 548 and Hoeschst. 
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Chemical complementation with IPP does not rescue ADEP4 treated parasites 
 
The apicoplast functions during the erythrocytic schizogony to provide isopentenyl 
pyrophosphate (IPP) (Jomaa et al., 1999; Ye and DeRisi 2011). By inhibiting the 
biogenesis of the apicoplast (Figure 41 above) how is ADEP4 affecting parasite cycle 
during blood stage? Therefore, to test whether this effect of ADEP4 is through the 
inhibition of the apicoplast function, P. falciparum was treated with ADEP4 and 
maintained under continuous exogenous IPP provision (Figure 16 above, under 
materials and methods section). 
Provision of IPP did not rescue the parasites from ADEP4 treatment at 10 ug/ml and 
30 µg/ml (Figure 42). At 30 µg/ml parasite growth was still inhibited within the first 
cycle. At 10 ug/ml, parasite transformation was not inhibited within the first cycle. 
Actually, parasite cycle was even much more prolonged (Figure 43 below) as 
compared to treatment with 10 ug/ml only (Figures 39 and 40 above). This indicates 
that, ADEP4 may not be only affecting the function of the apicoplast in IPP 
production, but ADEP4 has other targets besides inhibiting the apicoplast biogenesis 
and function, or perhaps the apicoplast has other unknown functions. 
 
 
 
Figure 42 Growth inhibition assay of ADEP4 on P. falciparum under IPP provision. Parasites supplemented with IPP were 
still affected by ADEP4 at 10 µg/ml (ADEP4-10 IPP) and 30 µg/ml (ADEP4 30-IPP) as compared to control treated with DMSO 
and IPP. Key: H24, H48, H72 and H96 means 24, 48, 72 and 96 hours post invasion respectively. Error bars represent 
standard deviation of the median. 
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Figure 43 Response of P. falciparum to treatment with ADEP4 at 10 µg/ml under exogenous provision with IPP. 
Untreated merozoites were able to invade erythrocytes, transformed into rings, trophozoites (Untreated Hour 24) and then into 
schizonts (Untreated Hour 48). This in turn gave rise to merozoites that were able to invade uninfected erythrocytes and initiate 
a second cycle during which they again transformed into rings (Untreated Hour 48), trophozoites (Untreated Hour 72) and then 
into schizonts which later formed merozoites that started a new cycle (Untreated Hour 96). Merozoites treated with ADEP 4 at 
10 µg/ml and maintained under exogenous provision with IPP were able to form rings (ADEP4+IPP Hour 24) but became 
arrested and transformed very late in the cycle into trophozoites (ADEP4+IPP Hour 42), which remained arrested (ADEP4+IPP 
Hour 48 and Hour 72). These in turn gave rise to merozoites very late, which were able to invade uninfected erythrocytes and 
initiate a second cycle (ADEP4+IPP Hour 96) at a time point when untreated parasites were already into their 3rd cycle 
(Untreated Hour 96). 
Chemical knockout of the apicoplast does not rescue ADEP4 treated parasites 
 
Cellular materials and organelles that cannot be synthesised denovo have to be 
replicated and passed on to the daughter cells. And because ADEP4 is affecting the 
apicoplast biogenesis and its segregation, therefore to test whether this could be 
affecting the parasite cell cycle, the apicoplast was chemically knocked out using 
clindamycin. The parasites were maintained under continuous exogenous IPP 
provision (Figure 17 above, under materials and methods section) and then treated 
with ADEP4 at 10 and 30 ug/ml under continuos IPP provision.  
 
Clindamycin induced inhibition of the apicoplast biogenesis (Figure 44) and 
consequently parasite growth (Figure 45). Upon early IPP provision, these parasites 
survived the effects of clindamycin (Figure 45). However, on treatment with ADEP4 
parasite growth was still inhibited (Figure 46). This confirms that ADEP4 has other 
targets besides the apicoplast.    
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Figure 44 Chemical knock-out of the apicoplast. As compared to untreated parasites, in clindamycin treated parasites 
biogenesis of the apicoplast was inhibited (Treated). Key: DIC: Cells, Apicoplast: apicoplast anti-ACP primary antibodies 
stained with Alexa 546 secondary antibodies; DNA: Nucleus stained with Hoeschst; Merge: Combination of Alexa 548 and 
Hoeschst. 
 
 
 
Figure 45 Chemical rescue of clindamycin treated parasites with IPP. As compared to untreated parasites (Control), 
clindamycin treated parasites were inhibited towards the end of the second cycle (Clindamycin). However, on early provision 
with IPP at 48 hours post invasion these parasites survived (Clindamycin + IPP). P values represent Kruskal wallis rank test of 
the medians and error bars represent standard deviation of the median. 
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Figure 46 Growth inhibition assay of ADEP4 on P. falciparum without the apicoplast under IPP provision. These 
Parasites without the apicoplast but maintained under a continuous IPP supply were still affected by ADEP4 at 10 µg/ml (IPP 
ADEP 10) and 30 µg/ml (IPP ADEP 30) as compared to the control treated with DMSO and IPP (IPP DMSO). Key: H24, H48, 
H72 and H96 means 24, 48, 72 and 96 hours post invasion respectively. Error bars represent standard deviation of the median. 
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DISCUSSION 
Part 1 
Clindamycin induced inhibition of apicoplast biogenesis and P. falciparum 
growth  
 
Exposure to clindamycin during the liver stage, results in the inhibition of the 
apicoplast biogenesis. Consequently this leads to inhibition of the parasite within the 
cycle of treatment (Friesen et al., 2010). However, during the blood stage this effect 
occurs in the subsequent cycle after clindamycin treatment (Goodman et al., 2007). 
To reconcile on these discrepancies, the first part of this study investigated the 
effects of synchronising clindamycin drug pressure and parasite cycle to the 
biogenesis of the apicoplast and growth of P. falciparum during blood stage (Figures 
5 and 6 above, under materials and methods). 
 
The data from this study demonstrates that, clindamycin exposure before invasion 
leads to the inhibition of the apicoplast biogenesis (Figure 22 - 25). Consequently, 
this impairs the egress machinery (Figures 31 - 34) leading to the arrest of the 
parasites as schizonts containing merozoites that are not able to egress (Figure 21). 
An overview of the egress mechanism, biogenesis, function and maintenance of the 
apicoplast in P. falciparum during blood stage, can provide an explanation for these 
observations. 
Egress Mechanism 
 
During its life cycle P. falciparum is restricted to live inside its host cell within a 
parasitophorous vacuole. In oder for its life cycle to progress, it must come out of the 
host cell through a process called egress and then invade another one. While in the 
liver and blood stages, egress is utilised by merozoites to get out of the hepatocytes 
and erythrocytes respectively. In its life cycle in the mosquitoe, gametocytes utilise 
egress to get out of the erythrocytes ingested during a blood meal. Finally 
sporozoites also utilize egress to get out of the oocysts in the mosquito midgut. 
During the blood stage, egress is a tightly regulated process requiring the enzyme 
Protein Kinase G (PKG) (Collins et al., 2013). PKG functions by regulating 
phosphoinositide metabolism and intracellular calcium ion levels (Ca2+) (Brochet et 
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al., 2014). It does this by activating the production of inositol - 1,4,5 - triphosphate 
(I145TP) (Brochet et al., 2014), which is an activator of Ca2+ release from the 
endoplasmic reticulum (Agarwal et al., 2013). This leads to an increase in 
intracellular Ca2+ (Agarwal et al., 2013; Collins et al., 2013; Glushakova et al., 2013),  
This increase in intracellular Ca2+ in-turn activates the exocytosis of the enzyme P. 
falciparum subtilisin-like protein 1 (PfSUB1) (Agarwal et al., 2013; Collins et al., 
2013), from exonemes to the parasitophorous vacuole (Yeoh et al., 2007). In the 
parasitophorous vacuole, PfSUB1 in-turn mediates the activation of other proteins 
required for egress, namely: serine like antigens (SERAs) (Collins et al., 2013) and 
P. falciparum perforin like proteins (PfPLPs) (Garg et al., 2013). Eventually 
merozoites become released and then initiate another cycle. 
Biogenesis and function of the apicoplast  
 
During erythrocytic schizogony, in wild type parasites, there is normal apicoplast 
biogenesis and function (Figures 22 - 25). The organelle is therefore able to grow, 
branch and get segregated to merozoites. These are then able to egress, invade 
uninfected erythrocytes and develop normally (Figure 21). But in clindamycin treated 
parasites, at first, there is normal apicoplast biogenesis and function (Figures 22 - 
23). The organelle is able to grow, branch and get segregated to daughter cells, 
which are able to egress, and then invade uninfected erythrocytes. But they begin to 
develop abnormally in terms of the apicoplast morphology (Figures 24 - 25) and 
parasite stages (Figure 21). 
 
In regard to the parasite stages, they start as rings which transform normally to 
trophozoites that in-turn transform to schizonts. However, these do not egress and 
thereby become unable to initiate another cycle (Figure 21), the so called delayed 
death (Surolia et al., 2004; Burkhardt et al., 2007; Dahl and Rosenthal 2007; 
Goodman et al., 2007). In regard to the apicoplast, they begin with a small apicoplast 
that is dot like but its biogenesis becomes affected and indeed its morphology 
becomes abnormal (Figure 25). It does not branch and segregate like in the previous 
cycle or like in wild type parasites (Figures 22 – 25). Thereby not performing its 
biological function of IPP production (Yeh and Derisi 2011). Consequently during the 
second cycle, clindamycin treated parasites rely on early exogenous IPP provision to 
progress to a third cycle (Figure 26). 
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IPP is required for the prenylation of Rab proteins in order for them to perform their 
cellular functions (Howe et al., 2013; Alberts et al., 2008). Due to the interdepence 
between a functional phosphoinositide metabolism and functional Rab proteins at 
micro-domains (Alberts et al., 2008; Jean and Kieger 2012), clindamycin induced 
shortage of IPP would therefore be expected to inhibit isoprenylation of Rab proteins 
(Howe et al., 2013) and therefore their functions. Consequently, this would affect 
phosphoinositide metabolism. This shortage of IPP in turn would be expected to 
impair the egress machinery. This is because an inhibited phosphoinositide 
metabolism cannot respond to PKG induced hydrolysis of PI 4,5 BP to Inositol 1,4,5 
triphosphate (I145TP) (Brochet et al., 2014). Therefore, lack of I145TP would lead to 
the inability to stimulate the endoplasmic reticulum to release Ca2+ (Agarwal et al., 
2013; Brochet et al., 2014). This eventually would lead to lower intracellular Ca2+ 
which should impair the secretion of PfSUB1 from exonemes (Agarwal et al., 2013) 
and consequently the egress defect (Figures 21 and 28 - 34). 
 
While this is would be expected to result from the clindamycin induced inhibition of 
phosphoinositide metabolism and consequently Ca2+ signalling. However, there is no 
significant difference in phosphoinositide metabolism and calcium signalling in 
clindamycin treated parasites as compared to the untreated parasites (Figures 35 - 
37). Because early treatment with IPP and zaprinast can rescue clindamycin arrested 
parasites (Figures 26 and 28), their provision to clindamycin arrested schizonts would 
be expected to reverse the clindamycin induced effects on the inhibition of P. 
falciparum. Howecer, IPP and  zaprinast rescue had no effect on phosphoinositide 
metabolism (Figures 36 and 37) and calcium signalling (Figure 35). But they both 
reversed clindamycin induced inhibition of PfSUB1 secretion (Figure 33 and 34), at 
least in some cells in the case of zaprinast. How then IPP and zaprinast reverse 
clindamycin induced inhibition of PfSUB1 secretion remains a question to be 
answered. 
Maintenance of the apicoplast 
 
Interestingly, clindamycin treated parasites can be rescued by the provision of IPP 
(Figure 26). However, this rescue is only possible for the first half of the second cycle 
(Figure 26) and provision of the IPP does not rescue the parasites thereafter (Figure 
26). This could mean that either the daughter cells inherit reserves of IPP from the 
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mother cell, or the apicoplast that they inherit, is functional for the time period after 
invasion to the time point where rescue with IPP is no longer possible. 
 
But bearing in mind that during the second cycle, clindamycin treated parasites 
undergo normal transformation from rings to schizonts that in-turn do not egress 
(Figure 21). On one hand, since therefore these parasites can be able to survive 
without the need of IPP rescue from the beginning of the second cycle (Figure 26) 
and on the other hand, since they have an abnormal apicoplast (Figure 25), this 
indicates that they only need a source of IPP. Therefore eliminating the possibility 
that they inherit reserves of IPP from the mother cell.  
 
Furthermore, antibiotic treated parasites lose the apicoplast and its genome (Ye and 
DeRisi 2011) and they can continue to survive without this essential organelle under 
exogenous IPP supply (Ye and DeRisi 2011). In other studies, interruption of 
proteins/pathways in the apicoplast results in the loss of this organelle (Mazundar et 
al., 2006; Tawk et al., 2011; Gisselberg et al., 2013) and delayed death of the 
parasites (Mazundar et al., 2006; Tawk et al., 2011).  To survive these apicoplast-
less parasites rely also on the provision of exogenous IPP (Gisselberg et al., 2013). 
Therefore, the parasites inherit a fully functional apicoplast that later becomes 
abnormal.  
 
Considering that clindamycin induces inhibition of the apicoplast protein translation 
(Camps et al., 2002) and consequently inhibition of its biogenesis, both during liver  
(Friesen et al. 2010) and blood stage ((Figures 22 - 25) and Goodman et al., 2007; 
Ye and DeRisi 2011)), what factor is required to maintain apicoplast biogenesis? In 
other words, why does its biogenesis become inhibited? And in-fact, looking at the 
blood stage why does this occur at later time points during the 2nd cycle post 
clindamycin exposure and not the earlier time points? Not even during the first cycle? 
 
This suggests that Plasmodium inherits a fully functional apicoplast and a certain 
factor (henceforth called factor X). This factor must be continuosly synthesised or 
supplemented for it to maintain the apicoplast biogenesis. This is important in order 
for the later to perform its biological role of IPP production during the blood stage 
(Jomaa et al., 1999; Ye and DeRisi 2011) and fatty acid during the liver stages (Yu et 
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al., 2008; Vaughan et al., 2009). Therefore, based on the difference in terms of the 
number of daughter cells between the liver and blood stages of Plasmodium, 
averagely 10,000 vs 20 respectively, the reason due to the different effects of 
clindamycin on these two stages of the parasite cycle is probably due to quantitative 
differences.   
 
Bearing this in mind, that Factor X is inheritated from the mother cell, it therefore 
becomes depleted during the liver stage by dilution due to its inheritance from 1 
parent cell to averagely 10,000 daughter cells. Therefore it must be replenished 
otherwise if not and as seen in Friesen et al., inhibition of apicoplast biogenesis 
occurs within the cycle of drug application (2010). As opposed to the liver stage, 
during the blood stage, one parent cell give rise to averagely 10-32 daughter cells, 
and each of these (assuming they all invade and rupture) in turn give rise to again 
averagely 10-32 daughter cells, therefore factor X is not diluted as much as in the 
former. Consequently it is passed on to a new generation of daughter cells. But at 
some point, it becomes depleted by further dilution resulting in delayed death. But 
what could this mysterious factor X be? 
 
The apicoplast Fe-S cluster biosynthesis pathway has been shown to be important 
for the maintenance of the apicoplast. This is because, it functions to provide Fe-S 
cofactors to apicoplast based proteins and pathways (i.e. ferredoxin redox system, 
Lipoate synthesis, tRNA modifications pathway, and the enzyme IspH of the 
isoprenoid biosynthesis pathway). As a proof, inhibition of this pathway, leads to the 
loss of the apicoplast and its genome. This is in contrast to the inhibiton of the 
isoprenoid biosynthesis pathway by the antibiotic fosmidomycin. However, in both 
cases, IPP supplementation rescues the parasites (Gisselberg et al., 2013). In 
addition, studies in Toxoplasma gondii, a model apicomplexan parasite, implicate the 
type II fatty acid (FASII) (Mazundar et al., 2006) as well as a posphotidylinostiol 3 
monophosphate (PI3P) mediated endosomal vesicular protein trafficking to the 
apicoplast (Tawk et al., 2011) to play a role in maintaining the biogenesis of the 
organelle. 
 
Considering that the apicoplast imports a huge bulk of proteins from the nucleus, 
approximately 545 (Ralph et al., 2004), and that its genome has only 64 genes, 
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majority being tRNAs and transcription factors (Wilson et al., 1996). Thus, a great 
majority of proteins are imported from the nucleus to the apicoplast (Waller et al., 
1998). Therefore, could it be that, the inability of clindamycin treated parasites to 
import and process proteins from the nucleus (Goodman et al. 2007; Ye and DeRisi 
2011), indicate a defective apicoplast protein import machinery preceding these 
events? Hence, could the apicoplast protein importation machinery (Waller et al., 
1998) complement the above-mentioned pathways to maintain its biogenesis? 
 
In other words, clindamycin induced inhibition of the apicoplast protein translation 
(Camps et al., 2002) would result in the absence of functional apicoplast proteins. 
These include part of the protein import machinery i.e. ClpM (formerly known as ClpC 
or Hsp93) and post-translation modification protein i.e. SufB (Waller and McFadden 
2005). This could results in two consequences: inability of the apicoplast to import 
proteins and perform post-translation modification of imported as well as the 
expressed proteins. These in general could reduce the functional protein pool in the 
apicoplast i.e. house keeping and metabolic proteins. The absences of house 
keeping proteins would inhibit transcription and translation of the apicoplast genome.  
Consequently this would lead to the inhibition of apicoplast replication, resulting in 
daughter cells with no apicoplast. These daughter cells therefore become deprived of 
the essential metabolic products from the apicoplast e.g. IPP during blood stage. 
 
Studies on other plastids implicate ClpC to play a role in protein import (Constan et 
al., 2004; Kovacheva et al., 2007) and iron homeostasis (Wu et al., 2010). Plants that 
have a mutant ClpC exhibit chlorosis, but they can be rescued by expression of wild 
type clpc1 and or watering with water enriched with iron (Wu et al., 2010). These 
mutants have defects in the proteins needed to import iron from the cytoplasm into 
the chloroplast (Wu et al., 2010). Thus defective clpc1 results in the inability to import 
iron-importing proteins into the chloroplast (Wu et al., 2010). Therefore perhaps, this 
mysterious factor that is required to maintain the apicoplast could be ClpM. 
 
To summarise, the data from the first part of this study demonstrate that by producing 
IPP, the apicoplast plays a role during egress. These findings expand the previous 
understood model on the antibiotics mode of action in P. falciparum to involve the 
inhibition of egress machinery during erythrocytic schizogony (Figure 45).  
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Part 2 
Acyldepsipeptides induced inhibition of apicoplast biogenesis and P. 
falciparum growth 
 
Based on the bacterial toxicity of ADEPS (Brötz - Oesterhelt et al., 2005; Sass et al., 
2011) and the bacterial nature of the apicoplast (Wilson et al., 1996), the aim of the 
second part of this study was to determine whether ADEPS can inhibit biogenesis of 
the apicoplast and therefore whether they can act as antimalarial drugs. This was 
tested by studying the function and biogenesis of the apicoplast in P. falciparum 
under treatment with ADEPS (Figures 14 and 15 above, under materials and 
methods). 
 
ADEP 1 at 10 µg/ml did not have any effect on the biogenesis and function of the 
apicoplast (Figure 41) and therefore it did not inhibit parasite growth (Figure 38) but 
at 30 µg/ml ADEP1 inhibited parasite growth at around 72 hours post invasion 
(Figure 38). On the contrary, ADEP4 inhibited parasite growth and development at 
similarly low and high concentrations (Figure 39). However, this inhibition was 
different such that ADEP4 at 30 µg/ml demonstrated immediate inhibition, whereby, 
upon invasion, the merozoites were able to transform into rings but got arrested 
within 24 hours. However, ADEP4 at 10 µg/ml interestingly induced a phenotype 
characterized by slow parasite growth with a lag phase of 12-24 hours (Figure 39 -  
40). As compared to the control, the biogenesis of the apicoplast in these parasites 
was inhibited (Figure 41 A and B). At the time point where it should have undergone 
segregation into the daughter cells it appeared branched (Figure 41 A and B), a 
phenotype reminiscent of filamentation in bacterial cells treated with ADEPS (Brötz - 
Oesterhelt et al., 2005; Sass et al., 2011). This suggested that ADEP4 induced 
inhibition of the apicoplast biogenesis and function. 
 
However, supplementation of its biological function during erythrocytic schizogony by 
continuous exogenous supply of IPP (Figures 42 and 43) or knocking it out 
chemically did not rescue the parasite from the effects of ADEP4 (Figures 42, 43 and 
46). This prooved that despite its bacterial nature, in P. falciparum, the apicoplast is 
not the only target of ADEPS, rather, the target are apicoplast dependent and 
apicoplast independent (Figure 46). 
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Furthermore, based on its ancestral origin, the apicoplast originated from 
cyanobacteria which is a gram negative bacteria (Waller and McFadden 2005) and 
ADEPS have only been shown to act on gram positive bacteria (Brötz - Oesterhelt et 
al., 2005; Sass et al., 2011). This indicates perhaps ADEPS are unable to penetrate 
the membranes of the apicoplast. But in this case how are ADEPS acting on P. 
falciparum?   
 
Considering that ADEPS in bacteria target caseinolytic protease (ClpP) (Brötz - 
Oesterhelt et al., 2005; Sass et al., 2011) and since P. falciparum has a ClpP too 
(Bakkouri et al., 2010), it might be possible that its also targeted by ADEP4. 
Therefore it might induce cellular damages within the host cell too. This would then 
result in the observed slowed parasite´s cycle during blood stage (Figures 39, 40, 41 
and 42). 
 
Because in other studies; DNA damage is associated with slow growing cells 
compared to fast or normal growing cells (Van Dijk et al., 2015). Indeed the antibiotic 
resveratrol by inducing DNA damage in bacteria cells stimulates DNA damage repair 
processes. This in-turn acts by inhibiting cell division. The cells get arrested as 
filamented structures (Hwang and Lim 2014). Threfore, it might be also possible that 
ADEP4 is simply toxic to P. falciparum. 
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Figure 47 Summary. During blood stage of P. falciparum; Normally, first a merozoite invades an erythrocyte, then it undergoes 
transformation and multiplication which is coupled to the biogenesis of the apicoplast, that grows, branches and get segregated 
to the daughter merozoites.These eventually egress and continue the cycle (A). According to the current model on the antibiotic 
mode of action, exposure to apicoplast’s protein translation inhibitory antibiotics post invasion during blood stage, results in 
normal apicoplast biogenesis and parasite growth during the first cycle. The parasite produces merozoites that egress, invade 
uninfected erythrocytes but the apicoplast biogenesis and function become inhibited, consequently the parasite becomes 
arrested and does not progress to a new cycle. However, this left a misery regarding the fate of these parasites and the 
apicoplast as well, which is a different observation as compared to exposing the liver stage to antibiotics before invasion (B). 
Therefore to reconcile this discrepancy, this study mimicked the experimental set up in the liver stage study (Friesen et al., 
2010), by exposing the parasite to an antibiotic called Clindamycin before invasion (C). During the first cycle, parasite 
development and apicoplast biogenesis was normal; the parasite produced merozoites that egressed, invaded uninfected 
erythrocytes and started a 2nd cycle. But two things happen: first, the apicoplast biogenesis becomes inhibited; it remains as a 
small rounded structure meaning that it was not able to grow, branch and segregate. Consequently the daughter cells do not get 
a copy of it. Therefore it does not perform its function of IPP production and egress. Eventually, these daughter cells become 
arrested and do not egress. Early (but not late) supply of exogenous IPP (D) or zaprinast (E) to clindamycin treated parasites 
was interestingly in-turn able to rescue these parasites. This study, therefore expands the previous understood models on the 
function of the apicoplast and the antibiotics mode of action in P. falciparum during erythrocytic schizogony. Additionally, using 
ADEPS as a new class of antibiotics, this study shows their potential as antimalarial drugs; they are able to induce inhibition of 
the parasite in a yet unidentified mechanism. This includes inhibiting targets within and outside the apicoplast (F). Therefore 
they have potential to be used as antimalarial drugs. 
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CONCLUSIONS AND RECOMMENDATIONS 
 
The data from the first part of this study demonstrate that the timing of antibiotic 
exposure during erythrocytic schizogony of P. falciparum has no influence on their 
effects on the biogenesis and function of the apicoplast and consequently the growth 
of P. falciparum. However, by inhibiting the biogenesis and function of the apicoplast 
in P. falciparum during erythrocytic schizogony, antibiotics inhibit the egress 
machinery of the parasite (Figure 47). This demonstrates that the apicoplast plays a 
role in the egress of the parasite. Hence, by targeting these processes new 
intervention strategies can be generated to  fight the malaria burden in the world. 
 
The data from the second part of this study demonstrate that ADEP4 can inhibit P. 
falciparum, however, despite its bacterial nature the apicoplast is not the only target 
(Figure 47). ADEPS inhibits targets within and outside the apicolast. Therefore more 
work is needed to be done to identify the target of ADEPS in P. falciparum. 
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APPENDIX 
 
Supplementary Data 
 
 
Supplementary Figure 1 Agarose gel electrophoresis to confirm lack of DNA contamination. As compared to the positive 
control, CDNA sample amplified did not have a band of 400 bp which is the size of the expected amplicon for the primers pair 1 
(Table 2) indicating lack of DNA contamination. 
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Summary 
To clearly delineate developmental events under antibiotic exposure we decided to 
decouple potentially confounding effects of different time points of exposure. We 
therefore synchronized drug exposure and parasite cycle in vitro during erythrocytic 
schizogony of Plasmodium falciparum. Exposure of P. falciparum to clindamycin 
before invasion resulted in the inhibition of the apicoplast biogenesis and 
consequently parasite arrest. These apicoplast-less parasites demonstrated defects 
in egress, relying on an unusual early supplementation with Isopentenyl 
pyrophosphate (IPP) or Zaprinast, an indication of apicoplast function in the egress of 
P. falciparum. 
 
Introduction 
Human malaria is a disease caused by infection with Plasmodium. Through a bite by 
an infected mosquito, parasite stages known as sporozoites migrate to the liver and 
initiate liver stage of the parasite life cycle. The parasite undergoes transformation 
and multiplication, giving rise to about 10,000 merozoites, which get released into the 
bloodstream, invade erythrocytes and initiate blood stage of the parasite life cycle. 
The parasite again undergoes transformation into rings, trophozoites and eventually 
schizonts that produce about 10-32 merozoites, which invade uninfected erythrocytes 
to continue the blood stage. The parasite also transforms into gametocytes, which 
after a blood meal end up in a mosquito to continue its life cycle.  
Malaria remains a big health problem. During the year 2015, 214 millions cases and 
438,000 deaths of malaria were reported, a big reduction by about 1 billion and 6 
millions respectively, during the time period from the year 2001 to 2015 (WHO 2015 
A). This achievement is mainly due to the use of malaria control interventions; 
insecticide treated nets, indoor residual spraying and the use of artemisinin-based 
combination therapies (ACTs) (WHO 2015 A). In the later intervention strategy, 
artemisinins, which have a short half-life, are combined with other antimalarial drugs 
with a long-half life. This is in order to reduce chances of the parasites developing 
resistance towards them and therefore safeguarding their applicability as antimalarial 
drugs. Never the less, there have been reports of parasite developing resistance to 
artemisinins and ACTs (Dondorp et al., 2009; Ashley et al., 2014; WHO 2014), which 
poses a threat to the current development in the fight against malaria. To safeguard 
these achievements and continue to win the war against malaria other alternative 
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drugs need to be used. Antibiotics have recently gained importance in the fight 
against malaria, as a first line defense against artemisinin or ACTs resistant parasites 
(Dondorp et al., 2009) and in combination with other drugs they are recommended as 
back-up treatment measures (WHO 2015 B).  
The malaria parasite has an organelle known as the apicoplast, a very essential 
organelle. This is because it hosts a number of metabolic pathways: the type II fatty 
acid synthesis, non-mevalonate isoprenoid synthesis, heme biosynthesis, Fe-S 
cluster biosynthesis, lipoate synthesis, tRNA modifications and ferredoxin redox 
system (Ralph et al., 2004). By supplying the products of these pathways, it plays 
different stage specific-roles during the life cycle of the parasite. In Plasmodium 
falciparum, during the mosquito stage it functions to produce heme (Niagara et al., 
2013; Ke et al., 2014), liver stage to produce fatty acids (Yu et al., 2008; Vaughan et 
al., 2009) the blood stage to produce isoprenoid precursors known as isopentenyl 
pyrophosphate (IPP) (Jomaa et al., 1999; Ye and DeRisi 2011; Wiley et al., 2015).  
Owing to its prokaryotic nature (Wilson et al., 1996), it is amenable to inhibition by 
antibiotics (Goodman et al., 2007). Exposure of P. falciparum to clindamycin post 
invasion during erythrocytic schizogony results in normal parasite growth and 
apicoplast development, the parasites are then able to egress, invade erythrocytes 
but at some point inhibition of the apicoplast biogenesis occurs and consequently 
parasite growth (Burkhardt et al., 2007; Dahl et al., 2007; Goodman et al., 2007). 
Likewise, clindamycin exposure during liver stage, starting with the liver invasive 
stages (sporozoites), results in the parasites developing into full maturity with no 
difference to controls (Friesen et al., 2010). In stark contrast to the blood stage 
phenotype, biogenesis of the apicoplast was immediately inhibited and progeny were 
unable to cause blood stage infection (Friesen et al., 2010). To mimic this 
experimental setup we determined the effect of clindamycin immediate exposure 
starting with the parasite´s invasive stage (merozoites) during erythrocytic 
schizogony. We demonstrate that a functional apicoplast is required for the egress of 
merozoites during erythrocytic schizogony. 
Results 
Clindamycin inhibits egress of Plasmodium falciparum blood stages 
We studied the effects of synchronizing clindamycin drug pressure and parasite cycle 
during erythrocytic schizogony of P. falciparum. We did this by culturing P. falciparum 
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in vitro and then using cell cultures enriched for schizonts; we isolated merozoites, 
which we exposed to clindamycin before invasion (Figure 1A). Thus, cell cycle and 
start of exposure were synchronized (Figure 1A). We then monitored the parasite 
growth for 2 cycles. At the end of the first cycle clindamycin-exposed parasites were 
able to egress and invade uninfected erythrocytes. In this second replication cycle, 
we observed normal differentiation into rings, trophozoites and then into schizonts via 
bright field microscopy (Figure 1B). However, treated cultures remained arrested at 
the schizonts stage at a time point when untreated parasites had progressed to the 
third cycle (Figure 1B). This indicated that clindamycin inhibits egress of the parasite 
after two cycles.  
 
Inhibition of egress correlates with inhibition of the apicoplast biogenesis 
Since delayed exposure to clindamycin >6 hours post invasion during erythrocytic 
schizogony acts by inhibiting apicoplast biogenesis (Camps et al., 2002; Goodman et 
al., 2007; Ye and DeRisi 2011), we tested what effects; the synchronization of drug 
pressure and parasite cycle would have on the apicoplast biogenesis (Figure 1A). 
We assayed the biogenesis of the apicoplast by immunofluorescence assay and 
fluorescence microscopy. During the first cycle, in both the treated and untreated 
cultures, the organelle branched and segregated into daughter cells (Figure 2A and 
B). In contrast to untreated cultures (Figure 2C), towards the end of the second cycle 
apicoplast biogenesis appeared inhibited in the clindamycin-arrested schizonts 
(Figure 2D). This indicated that the inhibition of the apicoplast biogenesis and 
function preceded the inhibition of egress. 
 
Chemical rescue with isopentenyl pyrophosphate (IPP) complements the 
apicoplast function and reverses the inhibition of egress  
Antibiotic treated parasites can be rescued by provision of exogenous IPP, the key 
product of apicoplast biosynthesis in blood stage parasites (Ye and DeRisi 2011). 
Here, we tested the hypothesis that the pronounced egress defect is due to IPP 
starvation and thus, can be directly rescued by IPP supplementation. Surprisingly, 
the egress defect could not be rescued by IPP directly (-2 hours) and partial as well 
as full rescue required IPP provision at ≥ -8 hours and ≥ -38 hours prior to egress, 
respectively (Figure 3). Firstly, this suggests that the structural remnant of the 
apicoplast (Figure 2D and Supplementary Figure 1) is either incompletely or fully 
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non-functional during the second cycle. More importantly, it raises the curious 
question of what cellular function(s) IPP governs early on in the second cycle, which 
if absent, permits morphologically normal maturation yet interferes with parasite 
egress.  
 
Inhibition of cyclic nucleotide phosphodiesterase activity by zaprinast forces 
egress of clindamycin-arrested P. falciparum in an unusual manner  
Failure to directly rescue the egress defect by IPP led us to attempt to induce 
productive egress, i.e. egress of invasion-competent merozoites, by an alternative 
chemical option or simply, mechanically. First, we used zaprinast, a previously 
described inhibitor of cyclic nucleotide phosphodiesterase activity (Collins et al., 
2013). Zaprinast-induced surge of intracellular cGMP (Collins et al., 2013) would 
accelerate egress of invasion-competent merozoites when added to mature 
schizonts. We confirmed that zaprinast, when added at 43 hours to untreated 
schizonts, accelerated egress (data not shown) and did not block the progression to 
the next cell cycle (Figure 4A). Next, we attempted to force egress of clindamycin-
arrested schizonts with zaprinast, postulating that this may allow cell cycle 
progression. However, we observed a pattern reminiscent of rescue with IPP (Figure 
3), such that only induction started during the first half of the 2nd cycle resulted in a 
significant proportion of parasites progressing into the 3rd cycle (Figure 4B). 
Strikingly, no premature egress was seen in clindamycin treated cultures upon 
exposure to zaprinast at Hour 84 (data not shown). 
 
Merozoites mechanically released from clindamycin-arrested schizonts are 
non-invasive  
To mechanically force egress of the clindamycin-arrested schizonts we ruptured the 
arrested schizonts using a syringe filter (Boyle et al., 2010). First, we observed 
morphological normal merozoites (data not shown). However, these merozoites were 
unable to invade (Figure 5). Taken together, these data demonstrate that 
clindamycin-induced inhibition of apicoplast biogenesis and function results in 
defective egress and invasive capacities of 2nd generation (F2) progeny.  
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Clindamycin-induced inhibition of apicoplast function interferes with the 
secretion of Pfsub1, an essential step in the egress pathway 
From the above findings, we concluded that either an essential biochemical signaling 
pathway and/or components of the egress machinery are dysfunctional in these 
parasites. Because of the chemical refractoriness of egress-deficient parasites 
(which can mechanically be released), we asked ourselves whether this correlates 
with alterations in a known essential component of the egress machinery. Both the 
natural egress signal and zaprinast induce egress by activating protein kinase G 
(PKG) (Collins et al., 2013).  PKG in-turn functions to regulate the secretion of 
Plasmodium falciparum subtilisin like serine protease-1 (PfSUB1) (Collins et al., 
2013) from exonemes (Yeoh et al., 2007). Because of the central and essential role 
of PfSUB1 in parasite egress and invasion (Koussis et al., 2009; Collins et al., 2013), 
we determined its sub-cellular localization. Untreated cultures displayed a diffuse 
signal, characteristic of secreted PfSUB1 (Figure 6A and supplementary figure 2A). 
However, treated cultures had punctate signal, indicating lack of secretion of PfSUB1 
(Figure 6B and supplementary Figure 2B). This was reversed on early treatment with 
IPP (Figure 6.C and supplementary figure 2C) or zaprinast (Figure 5D and 
supplementary Figure 2D). Upon zaprinast treatment a normal, diffuse anti-PfSUB1 
staining was observed in a subset of cells, correlating roughly with the proportion of 
parasites rescued by zaprinast. We thus conclude that clindamycin-induced inhibition 
of the apicoplast biogenesis and function interferes with the secretion of PfSUB1, 
suggesting dysfunctional egress signaling in these parasites.  
 
Discussion 
By exploiting the prokaryotic nature of the apicoplast (Wilson et al., 1996), antibiotics 
can inhibit its house keeping functions or the metabolic pathways it hosts (Waller and 
McFadden 2005; Goodman et al., 2007). They however, produce different effects 
during the life cycle of the malaria parasite. During the blood stage, exposure to 
antibiotics post invasion leads to a delayed effect on the biogenesis of the apicoplast 
and inhibition of the parasite (Burkhardt et al., 2007; Dahl et al., 2007; Goodman et 
al., 2007). Similarly, antibiotics inhibit the apicoplast biogenesis and parasite growth 
during the liver stage, but on the contrary, they produce an immediate effect (Friesen 
et al., 2010). Therefore, to clarify this discrepancy, we mimicked the experimental 
design used during the liver stage (Friesen et al., 2010), and we set up a clear-cut 
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experiment during the blood stage by starting the exposure of merozoite to 
clindamycin before invasion. We show that during blood stage, a functional 
apicoplast is required during egress (Figure 1 and 2).  
According to the current model on the antibiotic mode of action during blood stage of 
P. falciparum; exposure to apicoplast’s protein translation inhibitory antibiotics post 
invasion, results in normal apicoplast biogenesis and parasite growth during the first 
cycle, the parasite produces merozoites that egress, invade uninfected erythrocytes 
but the apicoplast biogenesis and function becomes inhibited, consequently the 
parasite becomes arrested and does not progress to a new cycle (Surolia et al., 
2004; Burkhardt et al., 2007; Dahl et al., 2007; Goodman et al., 2007; Ye and DeRisi 
2011). This left a misery regarding the fate of these parasites. Supply of exogenous 
IPP to antibiotic treated parasites was interestingly in-turn able to rescue these 
parasites (Ye and DeRisi 2011). Therefore IPP was sufficient to uncouple apicoplast 
from parasite development demonstrating that during the blood stage, the apicoplast 
mainly functions to produce IPP (Jomaa et al., 1999; Ye and DeRisi 2011). IPP inturn 
functions in the isoprenylation of Rab proteins, phosphoinositide metabolism and 
vesicular trafficking for the biogenesis of the food vacuole (Howe et al., 2013). Using 
an approach based on synchronising-drug-exposure-and-parasite-cycle (Figure 1A), 
we show that during antibiotic-induced delayed death the parasites develop to late 
schizonts with second-generation merozoites (Figure 1B) but due to defects in the 
egress machinery (Figure 6) these merozoites are not able to egress (Figure 1B). We 
therefore expand the previous understood models on the function of the apicoplast 
and the antibiotics mode of action in P. falciparum during erythrocytic schizogony 
(Figure 7). 
Egress is a tightly regulated process, according to the current model, it requires 
cGMP-dependent Protein Kinase G (PKG) (Collins et al., 2013), which functions by 
regulating phosphoinositide metabolism and intracellular calcium ion levels (Brochet 
et al., 2014). An increase in intracellular Ca2+ in the cytoplasm is required during 
egress (Agarwal et al., 2013; Collins et al., 2013; Glushakova et al., 2013) to activate 
the exocytosis of P. falciparum subtilisin-like protein 1 (PfSUB1) (Agarwal et al., 
2013; Collins et al., 2013) from exonemes to the parasitophorous vacuole (Yeoh et 
al., 2007). PfSUB1 in-turn proteolytically mediates the activation of other proteins 
required for egress (serine-type SERA proteases (Collins et al., 2013) and P. 
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falciparum perforin-like proteins (PfPLPs) (Garg et al., 2013)) and invasion 
(merozoite surface proteins 1, 6 and 7 (MSP1, 2 and 7) (Koussis et al. 2009)). 
Inhibition of the apicoplast biogenesis and function by clindamycin inhibits PfSUB1 
secretion and consequently egress of the parasite (Figure 1,2 and 6). IPP was able 
to rescue the parasites from the egress arrest (Figure 3) by reversing this effect 
(Figure 6C and supplementary figure 2C). Based on the fact that IPP functions in the 
isoprenylation of Rab proteins, phosphoinositide metabolism and vesicular trafficking 
for the biogenesis of the food vacuole (Howe et al., 2013). Therefore, due to the 
interdependence between Rab proteins and phosphoinositide metabolism (Alberts et 
al., 2008; Jean and Kieger 2012), clindamycin induced shortage of IPP inhibits 
isoprenylation of Rab proteins and phosphoinositide metabolism (Howe et al., 2013). 
The latter can therefore not respond to PKG regulation (Brochet et al., 2014). Early 
supply of IPP can circumvent these effects and therefore rescue the parasite (Figure 
3 and 6C). 
Zaprinast however, was able to rescue some parasites from the egress arrest (Figure 
4B) by inducing secretion of PfSUB1 in some of the parasites (Figure 6D and 
supplementary figure 2D). This can be explained by considering the fact that egress 
of P. falciparum can be induced chemically by zaprinast (Collins et al., 2013) which 
acts to activate PKG by inhibiting cGMP phosphodiesterase (Collins et al., 2013), 
eventually activating Ca2+ signaling (Taniguchi et al., 2006; Brochet et al., 2014) and 
consequently leading to secretion of PfSUB1 (Collins et al., 2013).  
The different observations regarding the delayed effects of antibiotics during the 
blood stage (Surolia et al., 2004; Burkhardt et al., 2007; Dahl et al., 2007; Goodman 
et al., 2007; Ye and DeRisi 2011) as opposed to immediate effects during the liver 
stages of the parasites (Friesen et al., 2010), can be attributed to result from 
quantitative reasons due to the requirement of a high metabolism to form/maintain 
about 10,000 daughter cells during the liver stage as opposed to the blood stages 
which forms just about 10 daughter cells. Therefore, inhibition of the apicoplast 
biogenesis cannot be tolerated during the liver stage, however, during the blood 
stage, the parasite tolerates inhibition of protein translation in the apicoplast during 
the first cycle, but during the second cycle this cannot be tolerated. This indicates 
that there is a factor that is required to maintain biogenesis of the apicoplast but it 
becomes highly diluted and therefore depleted as a result of massive branching of 
the apicoplast required for its segregation to the 10,0000 merozoites during the liver 
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stage. However, during the blood stage the fewer merozoites formed do not require 
such a high dilution of this factor. Therefore, the apicoplast biogenesis is not affected 
during the first cycle. But during the second cycle this factor becomes further diluted 
and depleted. Consequently, the apicoplast biogenesis becomes inhibited and 
therefore it cannot be segregated to the second-generation merozoites (Figure 2). 
These become deprived of the apicoplast and the essential functions that it fulfills 
(Figure 2,3,6 and 7).  
The limitations of our study are that: we did not determine the state of development 
of the clindamycin-arrested schizonts, whether the merozoites are fully developed, 
whether they have parasite plasma membranes around them, as well as to 
investigate in detail the state of PfSUB1 in clindamycin-arrested schizont.  
This study clarifies the mode of action of antibiotics, which are currently components 
of rescue treatments for artemisinin resistant infections (Dondorp et al., 2009). The 
practical implication of these findings is that antibiotics could be used to dissect the 
egress pathway. 
 
Experimental Procedures 
Cell Culture 
Plasmodium falciparum lab strain 3D7 was cultured in vitro according to Trager and 
Jensen (1976) with a few modifications.  Briefly, P. falciparum was cultured in Human 
O+ erythrocytes at 5% haematocrit in culture medium containing RPMI 1640 
(Invitrogen) supplemented with (L glutamine and HEPES), 10% Albumax II 
(Invitrogen), 2% Human AB+ serum, 1% Hypoxanthine (ccpro) and 0.05% 
Gentamicin (Invitrogen) in 92% N2, 5% CO2, 3% O2.  Cultures development and 
growth were then followed by examination and counting parasitemia, using giemsa 
stained thin smears. 
 
In vitro Drug Exposure Before Invasion 
Merozoite isolation was done according to Boyle et al., (2010) with modifications.  
Briefly, P. falciparum cultures were tightly synchronized with D-Sorbitol (Lambros and 
Vanderberg 1979) and heparin (Boyle et al., 2010).  Then at 40 - 42 hours post 
invasion the cultures were incubated with E64 (trans - Epoxysuccinyl - L - 
leucylamido (4 - guanidino) butane (Sigma Aldrich) for 5-8 hours.  The cultures were 
then filtered in incomplete culture medium through 1.2 µm Syringe filters (Sartorius). 
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Equal portions of the merozoites filtrate were used to initiate different cultures that 
were treated as following: One portion of the filtrate was treated with 50nM 
clindamycin before invasion. Another portion of the filtrate was used to set up a 
negative control in which the merozoites were not exposed to drug treatment. Growth 
and development of the cultures was then followed by examination using giemsa 
stained thin smears and light microscopy for two cycles. 
 
Rescue with Isopentenyl Pyrophosphate (IPP) 
Rescue of clindamycin-arrested parasites with IPP was done according to Yeh and 
DeRisi (2011) with modifications. Briefly, different groups of cultures were exposed to 
clindamycin before invasion as described above. Then they were treated by adding 
200 µM of IPP (Sigma Aldrich) at different times post invasion, namely at 48, 60, 72, 
84 and 96 hours. As controls, one group of cultures exposed to clindamycin before 
invasion and the negative control were not treated with IPP. 
 
Induction of Egress with Zaprinast 
Induction of egress in clindamycin-arrested parasites with Zaprinast was done 
according to Collins et al., (2013) with modifications. Briefly, different groups of 
cultures were exposed to clindamycin before invasion as described above. Then they 
were treated by adding 100 µM of Zaprinast (Sigma Aldrich) at different times post 
invasion, namely: at 48, 60, 72, 84 and 95 hours. As controls, one group of cultures 
exposed to clindamycin before invasion and the negative control were not treated 
with Zaprinast. 
 
Immunofluorescence Assay 
Different groups of cultures were exposed to clindamycin before invasion as 
described above.  Then immunofluorescence assay (IFA) was done as described by 
Tonkin et al., (2004) and Collins et al., (2013) with few modifications.  Briefly, cells 
were harvested from cultures and washed with 1X PBS. They were then fixed. For 
apicoplast IFA, this was done using 4% Paraformaldehyde (AppliChem) and 0.75% 
Gluteraldehyde (Sigma Aldrich) in 1X PBS for 30 minutes at 37°C. For PfSUB1 IFA, 
this was done using 4% Paraformaldehyde (Agar Scientific) and 0.0075% 
Gluteraldehyde (Sigma Aldrich) in 1X PBS for 30 minutes at room temperature. They 
were subsequently washed with 1x PBS. Thin smears were then made on Poly - L - 
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Slides (Sigma Aldrich). Permeabilization was then done. For apicoplast IFA, this was 
done using 0.2% Triton X-100 (Carl Roth) in 1X PBS for 30 minutes at room 
temperature. For PfSUB1 IFA, this was done using 0.1% Triton X-100 (Carl Roth) in 
1X PBS for 10 minutes at room temperature. The cells were subsquently washed 
with 1X PBS. Blocking was then done. For apicoplast IFA, this was done using 
Blocking Aid Solution (Invitrogen) for 1 hour at room temperature in a humidified 
chamber. For PfSUB1 IFA, this was done using Bovine Serum Albumin (Roth) for 1 
hour at room temperature in a humidified chamber. Primary antibody was then 
applied: For apicoplast IFA, Anti-ACP primary antibody diluted in Blocking Aid 
Solution (Invitrogen) (1:250) was used and incubated for 2 hours in a dark humidified 
chamber at room temperature. For PfSUB1 IFA, Anti-PfSUB1 primary antibody 
diluted in PBS (Sigma Aldrich) /0.5% (v/v) Tween 20 (Sigma Aldrich) /1% (w/v) BSA 
(Roth) (1:250) was used and incubated for 1 hour in a humidified dark chamber at 
room temperature. The cells were then washed three times in 1X PBS. Secondary 
antibody was then applied and incubated for 1 hour in a dark humidified chamber at 
room temperature. For apicoplast IFA, Alexa Fluor 546 (Invitrogen) diluted in 
Blocking Aid Solution (Invitrogen) (1:1000) was used. For PfSUB1 IFA, Alexa Flour 
548 (Invitrogen) diluted in PBS (Sigma Aldrich) /0.5% (v/v) Tween 20 (Sigma Aldrich) 
/1% (w/v) BSA (Roth) (1:1000) was used. The cells were incubated for 1 hour in a 
humidified dark chamber at room temperature. They were then washed three times 
with 1X PBS. Hoechst 33342 (Invitrogen) diluted in 1x PBS (1:1000) was then added 
and incubated for 5 minutes in a humidified dark chamber at room temperature. The 
cells were then washed three times in 1X PBS. They were then mounted with Pro-
long Gold mounting solution (Invitrogen). The samples were then examined with a 
fluorescence microscope (Zeiss Observer.Z1). 
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Figure Legends 
Figure 1 Response of P. falciparum to Clindamycin. (A). P. falciparum blood 
stages were cultured in vitro. The cultures were then tightly synchronized and used to 
isolate merozoites. These merozoites were subsequently treated with clindamycin 
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before invasion. The cultures were then monitored at 12-hour intervals for 2 cycles by 
light microscopy. A control was set up with no drug exposure. (B). Thin smears of P. 
falciparum in vitro cultures during the second cycle post invasion. The bottom row 
represents culture treated with clindamycin and the top row is the control. Note the 
persistence of arrested schizonts beyond the end of the second cycle (hour 84) in 
clindamycin treated parasites into the third cycle (hour 96). Note that the average 
duration of the erythrocytic cell cycle in our culture of the 3D7 strain was 43 hours. 
 
Figure 2 Effect of clindamycin on P. falciparum apicoplast biogenesis. 
Immunofluorescence assay pictures of the apicoplast in P. falciparum blood stages.  
Apicoplast structures were visualized by an anti-acyl carrier protein (ACP), an 
essential ‘signature’ protein of the apicoplast. During, the first cycle in both the 
treated and the un-treated cultures biogenesis of the apicoplast was not affected (A 
and B). During the second cycle, biogenesis of the apicoplast was arrested in the 
clindamycin exposed, but not in control (C), cultures (D). 
 
Figure 3 IPP rescue of clindamycin treated parasites at different time points 
post invasion. Importantly, only parasites treated with IPP during the first half of the 
second cycle were able to progress to a third cycle (TR H48, TR H60, TR H72 and 
TR H78) but at different proportions as compared to the control. Key: TR48, TR60, 
TR72, TR78, TR84, TR96: Test sample treated with IPP at 48, 60, 72, 78, 84 and 96 
hours post invasion respectively. The experimental replicates are a minimum of 3 
independent experiments. Error bars indicate standard deviation. 
 
Figure 4. Zaprinast rescue of clindamycin arrested schizonts at different time 
points post invasion. (4A) Zaprinast induced egress of untreated late schizonts did 
not interfere with the invasiveness of the merozoites (4B) indicating what we would 
expect to see at the end of the cycle under zaprinast treatment. Treatment of 
clindamycin-arrested schizonts with Zaprinast at 48 hours post invasion was able to 
rescue the parasites. Key: ZH48, ZH60, ZH72, ZH84 and ZH95: Test samples 
treated with clindamycin before invasion and then with Zaprinast at 48, 60, 72, 84 or 
95 hours post invasion. Test: samples treated with clindamycin only. The 
experimental replicates are a minimum of 3 independent experiments. The statistical 
test used is Kruskal-Wallis rank test.  Error bars indicate standard deviation. 
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Figure 5 Invasion assay, determined by counting ring stages at 12 hours post 
invasion. As compared to the control merozoites released by mechanical rupture of 
clindamycin-arrested schizonts were not able to invade erythrocytes. The 
experimental replicates are four independent experiments. The statistical test used is 
Kruskal-Wallis rank test.  Error bars indicate standard deviation. 
 
Figure 6 Representative images from immunofluorescence assays of PfSUB1, 
a known component of the egress machinery, at the end of the second cycle. 
(A) In control cultures, the signal was diffuse, indicating regular secretion of PfSUB1. 
(B) In contrast, in clindamycin treated samples the signal was punctate indicating 
lack of PfSUB1 secretion. (C) This was reversed on rescue with IPP or  (D) zaprinast 
(both drugs applied at hour 48, i.e., 37 hours prior to egress). About half of the cells 
exposed to zaprinast early during the second cycle displayed normal PfSUB1 
staining pattern, indicating a correlation with the subset of parasites rescued by early 
exposure to zaprinast (Fig. 4B). 
 
Figure 7 A model for the role of the apicoplast during the egress of P. 
falciparum. According to the previous understood model, antibiotics inhibit 
biogenesis of the apicoplast and therefore its function in IPP production (B). This 
study further shows that antibiotics act during erythrocytic schizogony by inhibiting 
the egress of the parasite (C). This effect can be reversed by early rescue with IPP 
(D) or zaprinast (E). In demonstrating that, by producing IPP a functional apicoplast 
is required for PfSUB1 secretion and eventually egress during erythrocytic 
schizogony this study therefore expands the current understanding of its biology 
during erythrocytic schizogony.  
 
Supplementary Figure 1 Effect of clindamycin on P. falciparum apicoplast 
biogenesis. Immunofluorescence assay pictures of the apicoplast in P. falciparum 
blood stages at hour 66 during the second cycle.  Apicoplast structures were 
visualized by an anti-acyl carrier protein (ACP), an essential ‘signature’ protein of the 
apicoplast. In both the treated (A) and the clindamycin-treated cultures (B) 
biogenesis of the apicoplast was not affected.  
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Supplementary Figure 2A Immunofluorescence assay of PfSUB1 at the end of 
the second cycle. Shown here are immunofluorescence assay pictures of the 
localisation of PfSUB1 in P. falciparum untreated with clindamycin before or after 
invasion (C). In the various cells observed the appearance of PfSUB1 ranged from 
absent, weak to diffuse. 
 
Supplementary Figure 2B Immunofluorescence assay of PfSUB1 at the end of 
the second cycle. Shown here are immunofluorescence assay pictures of the 
localisation of PfSUB1 in P. falciparum treated with clindamycin before invasion (T). 
In the various cells observed the appearance of PfSUB1 was strong and punctate. 
 
Supplementary Figure 2C Immunofluorescence assay of PfSUB1 at the end of 
the second cycle. Shown here are immunofluorescence assay pictures of the 
localisation of PfSUB1 in P. falciparum treated with clindamycin before invasion and 
then with zaprinast at 48 hours post invasion (Z). The appearance of PfSUB1 was 
strong and punctate in some cells and in others it ranged from absent, weak to 
diffuse 
 
Supplementary Figure 2D Immunofluorescence assay of PfSUB1 at the end of 
the second cycle. Shown here are immunofluorescence assay pictures of the 
localisation of PfSUB1 in P. falciparum treated with clindamycin before invasion and 
then with IPP at 48 hours post invasion (I). The appearance of PfSUB1 ranged from 
weak to diffuse. 
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ABSTRACT 
Background 
We tested an experimental class of antibiotics called acyldepsipeptides (ADEPS) on 
whether they can target the biogenesis or function of the apicoplast in P. falciparum 
during erythrocytic schizogony and therefore whether they have antimalarial activity.  
Results 
Despite ADEPS not being able to target the apicoplast biogenesis or function they 
were able to inhibit growth of P. falciparum interestingly inducing a phenotype 
characterized by slow parasite growth. 
Conclusion 
ADEPS have antimalarial activity 
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Background 
 
Malaria being a global health disaster necessitates development of intervention 
strategies. Parasites development of resistance to antimalarial drugs is however a 
huge hindrance to the fight against malaria. Therefore there is need for the 
development of new antimalarial drugs not only for combination therapy but also as a 
back up. 
The malaria parasite harbors the apicoplast, an organelle of prokaryotic origin [1]. 
This organelle has essential functions and is an established drug target [2, 3, 4, 5, 6,   
7, 8, 9,10]. Indeed a number of classical antibiotics are able to inhibit its biogenes or 
function and consequently inhibiting the parasite [3, 11, 12, 13, 14, 15, 7]. 
Acyldepsipeptides (ADEPS) are 6 different compounds (ADEPS 1 to 6) produced 
from a parent compound called A54556 complex [16, 17]. In bacteria, ADEPS act via 
a unique mode of action [17]. They bind to ClpP protease, activating it uncontrollably 
[17, 18]. The unregulated ClpP then preferentially targets bacterial cell division 
machinery [17, 19].This results in the inhibition of bacterial cell division, with 
parasites ending up as filamented or swollen cells [19, 17].  
Since the apicoplast is bacterial in nature, we therefore determined whether  ADEPS 
can target the apicoplast and inhibit the growth of P. falciparum. 
 
RESULTS 
 
ADEP 4 slows down the cell cycle of Plasmodium falciparum 
 
To determine whether ADEPS can inhibit P. falciparum, we exposed the parasites in 
vitro to different types of ADEPS: ADEP 1 and 4. ADEP 1 did not show any activity 
against P. falciparum (data not shown). But ADEP 4 demonstrated different effects, 
at 30 µg/ml it inhibited parasite growth within 24 hours during the first cycle and at 10 
µg/ml it induced slow parasite growth as depicted by Low parasitemia (Figure 1A) 
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and delayed parasite cycle during blood stage  (Figure 1B). This indicated that 
ADEP1 had no effect against P. falciparum but ADEP4 was active.   
 ADEP4 induces filamentation of the apicoplast 
The apicoplast is bacterial in nature [1] and since it cannot be formed de novo it has 
to be inherited from the mother cell to the daughter cell. Therefore it undergoes 
biogenesis whereby  it starts as a tiny structure which grows, branches and 
eventually gets segregated to the daughter cells, which later egress and invade 
uninfected erythrocytes [2]. ADEP4 demonstrates effects against P. falciparum 
(Figure 1), therefore to determine whether the apicoplast was the target; we studied 
its biogenesis using immunofluorescence assay at the end of the first and second 
cycle, under treatment with ADEP 1 or 4 at 10 µg/ml. The apicoplast biogenesis 
under ADEP 1 was not affected both during the end of the first and second cycle 
(Fig. 2A and 2B). However, under ADEP 4 treatments, at the time point whereby it 
should have undergone segregation i.e. at the end of the first and second cycle, it 
remained still branched (Fig. 2A and 2B). This morphology is typical of younger 
parasite stages (i.e. trophozoites). This confirms the delayed parasite cycle during 
the blood stage and indicates inhibition of the apicoplast biogenesis. 
Chemical complementation with IPP does not rescue ADEP4 treated parasites 
 
The apicoplast functions during the erythrocytic schizogony to produce isopentenyl 
pyrophosphate (IPP) [3, 7]. Therefore, to determine whether this effect of ADEP4 on 
P. falciparum (Figure 1) is through the inhibition of the apicoplast function; we 
supplemented the apicoplast function by treating P. falciparum with ADEP4 under 
continuous exogenous IPP provision. Provision of IPP did not rescue the parasites 
from ADEP4 treatment at 10 ug/ml and 30 µg/ml (Figure 3A). These parasites 
appeared to lag even much behind (Figure 3B) as compared to when treated with 
ADEP4 only (Figure 1B). This indicates that, ADEP4 does not affect the function of 
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the apicoplast in IPP production but ADEPS may have other unknown targets.  
Chemical knockout of the apicoplast does not rescue ADEP4 treated parasites 
 
Cellular materials and organelles that cannot be synthesised denovo have to be 
replicated and passed on to the daughter cells. And because ADEP4 is affecting the 
apicoplast biogenesis and its segregation, therefore to determine whether this was 
the reason behind the effects of ADEPS (Figure 1 and 2), we chemically knocked out 
the apicoplast and maintained these parasites under continuous exogenous IPP 
provision (Figure 4A and B). We then treated the parasites with ADEP4 at 10 and 30 
ug/ml under continuos IPP provision. However, parasite growth was still inhibited 
(Figure 4C). This confirms that the target of ADEP4 is not the apicoplast.    
DISCUSSION 
 
Based on the antibacterial activity of ADEPS [17, 19] and the bacterial nature of the 
apicoplast [1], we determined whether ADEPS can inhibit biogenesis of the 
apicoplast and therefore whether they can act against P. falciparum. ADEP1 had no 
activity against P. falciparum (data not shown). However, ADEP4 demonstrated 
immediate parasite inhibition at high concentration and at low concentration, it 
induced slow parasite growth (Figure 1A and B). Since this effect however was not 
due to it targeting the function of the apicoplast in IPP production (Figures 3 and 4), a 
possible hypothesis on how ADEP4 exert its effect on P. falciparum would be that: 
ADEPS are unable to penetrate the membranes of the apicoplast. This is because, 
based on its ancestral origin, the apicoplast originated from a cyanobacteria which is 
a gram negative bacteria [2] and ADEPS have only been shown to act on gram 
positive bacteria [17, 19]. Considering that ADEPS in bacteria target caseinolytic 
protease (ClpP) [17, 19] and since P. falciparum has a ClpP too [20], it might be 
possible that its also targeted by ADEP4. Therefore it might induce cellular damages 
within the host cell as well and this would then result in the observed effects (Figure 
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1 and 2). 
Conclusion 
 
We demonstrate that ADEPS can inhibit growth of P. falciparum and therefore they 
have potential to be used as antimalarial drugs.  
Materials and Methods 
 
Cell Culture 
 
Plasmodium falciparum lab strain 3D7 was cultured in vitro according to the protocol 
by Trager and Jensen [21]. Briefly, P. falciparum was cultured in Human O+ 
erythrocytes at 5% haematocrit in culture medium containing RPMI 1640 (Invitrogen) 
supplemented with L glutamine and HEPES, 10% Albumax II (Invitrogen), 2% 
Human AB+ serum, 1% Hypoxanthine (ccpro) and 0.05% Gentamicin (Invitrogen) in 
92% N2, 5% CO2, 3% O2 . Parasite growth was then followed by examination and 
counting parasitemia using giemsa stained thin smears. 
In vitro Drug Exposure Before Invasion 
 
Merozoites were isolated according to the protocol by Boyle et al., [22]. Briefly, P. 
falciparum cultures were tightly synchronized with D-Sorbitol [23] and heparin [22]. 
After 40 - 42 hours post invasion the cultures were treated with E64 (Sigma Aldrich) 
and incubated for 5-8 hours. The cultures were then filtered in incomplete culture 
medium through 1.2 µm syringe filter (Sartorius). Equal portions of the merozoites 
filtrate were used to initiate different cultures that were treated before invasion with 
either: ADEP 1 at 10 µg/ml and 30µg/ml, ADEP 4 at 10 µg/ml and 30µg/ml or 50nM 
clindamycin. A portion of the filtrate was used to set up a negative control in which 
the merozoites were not exposed to any drug treatment. Growth and development of 
the cultures was then followed by examination using giemsa stained thin smears and 
light microscopy for two cycles. 
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Rescue with Isopentenyl Pyrophosphate  
 
Cultures of P. falciparum were treated with IPP according to the protocol by Yeh and 
DeRisi [7]. Different groups of cultures were first exposed to ADEPS before invasion 
as described above. They were then treated by adding 200 µM of IPP (Sigma 
Aldrich) at 48 hours post invasion. As controls, one group of cultures exposed to 
ADEPS before invasion and the negative control were not treated with IPP. 
Chemical Knock - Out of the apicoplast 
 
Chemical knock-out of the apicoplast was performed according to the protocol by 
Yeh and DeRisi [7]. Briefly, merozoites were isolated as described above. They were 
subsequently treated with 50nM clindamycin before invasion and used to initiate 
cultures. Starting at 48 hours post invasion the cultures were treated by adding 200 
µM of IPP (Sigma Aldrich). Then after 48 hours, the culture media was replaced with 
new media and IPP. As controls, one group of culture exposed to clindamycin before 
invasion and the negative control were not treated with IPP. 
Localization assays of Apicoplast  
 
Localization assays of the apicoplast and PfSUB1 were performed using 
immunofluorescence assay (IFA) as described by Tonkin et al., [23]. Briefly, different 
groups of cultures were exposed to clindamycin before invasion as described above. 
Then cells were harvested from these cultures accordingly (Apicoplast after every 12 
hours for 2 cycles and PfSUB1 towards the end of the second cycle). They were then 
washed with 1X PBS and fixed using 4% Paraformaldehyde (AppliChem) and 0.75% 
Gluteraldehyde (Sigma Aldrich) in 1X PBS for 30 minutes at 37°C. After fixation, the 
cells were washed with 1x PBS and thin smears were made on Poly - L - Slides 
(Sigma Aldrich) and permeabilized by treating the cells with 0.2% Triton X-100 (Carl 
Roth) in 1X PBS for 30 minutes at room temperature. The cells were washed with 1X 
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PBS and blocked by treating the cells with Blocking Aid Solution (BAS) (Invitrogen) 
for 1 hour at room temperature in a humidified chamber. Anti-ACP primary antibody 
diluted 1:250 in Blocking Aid Solution (Invitrogen) was used. The cells were then 
incubated for 1-2 hours in a dark humidified chamber at room temperature. They 
were then washed three times with 1X PBS. Alexa Fluor 546 (Invitrogen) diluted 
1:1000 in Blocking Aid Solution (Invitrogen) was then applied as a secondary 
antibody. The cells were then incubated for 1 hour in a dark humidified chamber at 
room temperature and then washed three times with 1X PBS. Hoechst 33342 
(Invitrogen) diluted 1:1000 in 1x PBS was then added and the cells were incubated 
for 5 minutes in a humidified dark chamber at room temperature. The cells were then 
washed three times with 1X PBS. Finally, the cells were mounted with Pro-long Gold 
mounting solution (Invitrogen) and examined with a fluorescence microscope (Zeiss 
Observer.Z1). 
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Figure legends 
Figure 1 Growth inhibition assay of ADEP4 on P. falciparum. A). ADEP4 at 10 
ug/ml (ADEP 4 10) did not inhibit parasite growth while ADEP4 at 30 ug/ml (ADEP4 
30) inhibited parasite growth within the first cycle. Error bars represent standard 
deviation of the median. B). Giemsa thin smears of P. falciparum. As compared to 
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untreated parasites, parasites treated with ADEP4 at 10 ug/ml lagged behind in the 
parasite cycle during the blood stage. When they were supposed to be trophozoites, 
they were rings, when they were supposed to be schizonts, they were trophozoites 
and they only get to finish their first cycle (ADEP4 Hour 72), when the untreated 
parasites are already in the middle of their second cycle (Untreated Hour 72).  
Figure 2 Effects of ADEPS on the biogenesis of the apicoplast during the first 
(A) and second cycle (B). As compared to untreated parasites, ADEP1 had no 
effect on the apicoplast biogenesis. ADEP4 however inhibited the biogenesis of the 
apicoplast. Key: DIC: Cells, Apicoplast: apicoplast anti-ACP primary antibodies 
stained with Alexa 546 secondary antibodies, DNA: Nucleus stained with Hoeschst, 
Merge: Combination of Alexa 548 and Hoeschst  
Figure 3 Growth inhibition assay of ADEP4 on P. falciparum under IPP 
provision. A). Parasites supplemented with IPP were still affected by ADEP4 at 10 
µg/ml (ADEP4 10 IPP) and 30 µg/ml (ADEP4 30 IPP) as compared to control treated 
with DMSO and IPP. Error bars represent standard deviation of the median. B). 
Giemsa thin smears of P. falciparum. As compared to untreated parasites, parasites 
treated with ADEP4 at 10 ug/ml under exogenous IPP provision lagged much behind 
in the parasite cycle during the blood stage. They only get to finish their first cycle 
(ADEP4+IPP Hour 96), when the untreated parasites are already in their third cycle 
(Untreated Hour 96).  
Figure 4 Growth inhibition assay of ADEP4 on P. falciparum without the 
apicoplast under IPP provision. A). As compared to control, Clindamycin inhibited 
the apicoplast biogenesis towards the end of the second cycle. B). However, these 
parasites survived on provision with IPP (Clindamycin + IPP). C). These Parasites 
without the apicoplast but maintained under a continuous IPP supply were still 
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affected by ADEP4 at 10 µg/ml (IPP ADEP 10) and 30 µg/ml (IPP ADEP 30) as 
compared to the control treated with DMSO and IPP (IPP DMSO). P values 
represent Kruskal wallis rank test of the medians and error bars represents standard 
deviation of the median.  
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